

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05396 A1

(51) International Patent Classification⁷: **A61K 31/295**, (74) Agent: **WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036 (US).**

(21) International Application Number: **PCT/US00/18488**

(22) International Filing Date: **6 July 2000 (06.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/144,346 16 July 1999 (16.07.1999) US

(71) Applicant: **THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US).**

(72) Inventors: **SILVERSTEIN, Saul, J.; 69 Havemeyer Road, Irvington, NY 10533 (US). LIUM, Erik; Apt. #1, 1340 Palos Verdes Drive, San Mateo, CA 94404 (US). SCHWARTZ, Jennifer; Apt. 1D, 80 Haven Avenue, New York, NY 10032 (US).**

(81) Designated States (*national*): **AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FL, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.**


(84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **USE OF COBALT CHELATES FOR TREATING OR PREVENTING VIRUS INFECTION**



(57) Abstract: A method of treating a subject infected with a virus or a method of preventing viral infection of a subject comprising administering to the subject an effective amount of a compound having structure (1), wherein L=L'=2-methylimidazole

WO 01/05396 A1

PCT/US04/19812

**USE OF COBALT CHELATES FOR
TREATING OR PREVENTING VIRUS INFECTION**

5

This application claims priority of U.S. Provisional Application No. 60/144,346, filed July 16, 1999, the contents of which are hereby incorporated by reference.

10 This invention has been made with government support under grants from the Public Health Service RR10506 (Shared Instrumentation Grant), CA13696 (Herbert Irving Cancer Center), and AI-33952. Accordingly, the U.S. Government may have certain rights in the invention.

15

Throughout this application, various publications are referenced by author, date and citation. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to 20 more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

Background of the Invention

25 Viral infection is the cause of a number of human and animal diseases throughout the world. Considerable effort has been focused on developing treatments for preventing infection and reducing virus pathogenesis.

30 Infection by the alphaherpesviruses herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) result in a variety of viral diseases which are distributed worldwide including oral and genital epithelial lesions, encephalitis and ocular keratitis (15, 16, 20, 87, 91). Among these, herpetic ocular infection 35 is the leading infectious cause of blindness in developed countries (45, 52, 53, 87). In immunocompetent and immunocompromised patients herpesvirus infections are among the most frequent causes of virus disease (74, 84, 92).

-2-

Herpesvirus infections are characterized by their ability to establish latency and reactivate from the latent state (76). Consequently, both primary and recrudescent infections in immunocompromised patients are life-threatening (74, 84, 92).

5

Several medications exist which are approved for use in the treatment of herpesvirus infections, e.g. aciclovir ("ACV"), penciclovir, valaciclovir, and famciclovir. Derivatives of these are being developed and/or undergoing clinical trials

10 (2, 5, 17). In general these drugs are nucleoside analogs and thus their primary target is virus DNA synthesis (27, 32).

A majority of these pharmaceuticals are activated by the HSV protein thymidine kinase ("tk"). Although many of these drugs and their prodrugs target an aspect(s) of the 15 herpes life cycle, they are also proving to be mutagenic or otherwise cytotoxic. In addition, many drug resistant strains are appearing with increasing frequency (13, 14, 17, 29, 30, 51, 66, 77). It is not surprising that these strains have been found to be resistant to the most commonly used of these

20 treatments, ACV. Resistance appears to arise from either altered activation of the drug via aberrant tk expression or substrate specificity (18, 28) or by mutations in other enzymatic processes such as DNA polymerase activity (13, 14, 44, 66, 77). Therefore, new drugs need to be developed which 25 target other aspects of the virus life cycle in order to find treatments which are most effective against the existing drug-resistant strains as well as all the known herpes viruses.

30 U.S. Patent No. 5,756,491 relates to antiviral cobalt-organic compounds which are also known as the CTC series of compounds. The disclosures of U.S. Patent No. 5,756,491, as well as U.S. Patent No. 5,049,557 referred to therein, in their entireties are hereby incorporated by reference into 35 this application in order to more fully describe the state of the art as known to those skilled therein as of the date

-3-

of the invention described and claimed herein.


The CTC series of cobalt containing compounds possess anti-inflammatory (93) and anti-viral activity (3, 22, 25, 5 88). Several CTC complexes have moderate activity *in vitro* and *in vivo* against HSV-1 and 2, varicella-zoster virus (VZV), cytomegalovirus and Epstein-Barr virus (3, 22, 25, 88). Previous studies show that CTC-96, structure of which is shown in Figure 1, a derivative of CTC-23 (3, 22, 25, 88, 10 93), is the least cytotoxic and most effective of the CTC compounds against HSV-1 and 2 (3, 22). CTC-96 is also effective in inhibiting HSV-1 production in tissue culture (3). In the rabbit eye model, CTC-96 is able to reduce the corneal surface level of HSV-1 and facilitate the recovery 15 from dendritic keratitis (3, 22). It has been suggested that the anti-inflammatory properties of the CTC complexes may aid in recovery from ocular disease (3). Although the anti-herpetic activity of the CTC series has been known for many years, neither the mechanism by which it acts nor the 20 stage of the virus life cycle at which CTC-96 exerts its inhibitory action on HSV-1 has been elucidated.

-4-

Summary of the Invention

The subject invention provides a method of preventing the infection of a cell by a virus comprising contacting the cell with a compound having the structure:

5



10


15

wherein L=L' = 2-methylimidazole.

The subject invention also provides a method of treating a cell infected by a virus comprising contacting the cell with a compound having the structure:

25

30



wherein L=L' = 2-methylimidazole.

35

-5-

More particularly, the inventive method is useful against either an enveloped viruses or a non-enveloped virus.

In a preferred embodiment, the inventive method is useful
5 against an enveloped virus selected from the group consisting
of varicella-zoster virus, vesicular stomatitis virus, and
influenza virus.

In another preferred embodiment, the inventive method is
10 useful against a non-enveloped virus selected from the group
consisting of poliovirus and adenovirus.

-6-

Description of the Figures

Figure 1 is a schematic diagram of the chemical structure of CTC-96. 2-MeI denotes 2-methylimidazole.

5 Figures 2A and 2B show the effect of exposure to and dilution of CTC-96 on HSV-1 plaque formation in tissue culture. Vero cell monolayers were infected with HSV-1 in the presence of various concentrations of CTC-96. After several days at 37°C, the number of plaques formed were quantitated. Data in 2A
10 represent the average number of plaques formed from four experiments. Data in 2B represent the average number of plaques from two experiments.

Figure 3 shows the effect of CTC-96 on HSV-1 attachment. ³H labeled HSV-1 was adsorbed to Vero cell monolayers (MOI=100) on ice at 4°C for 45 min in the presence or absence of 50 μ g/ml of CTC-96. The infected cells were washed several times and the amount of free versus bound virus was quantitated (see Materials and Methods). Data are represented
20 as the relative amount of counts per minute (cpm) and are the average of four samples.

Figure 4 shows the accumulation of virus specified proteins in the presence of CTC-96. Vero cell monolayers were either
25 mock-infected (M) or infected with HSV-1 at a MOI of 5 in the presence (+) or absence (-) of 50 μ g/ml of CTC-96. CTC-96 was added either at the onset of infection (0) or at 1 hour postinfection (1). Infected cell extracts were harvested at the indicated hour postinfection (Hpi). Western blot analysis
30 was performed using either (a) the rabbit polyclonal antibodies CLU7 (anti-ICP0) and CLU38 (anti-ICP27) or (b) the rabbit polyclonal antibodies R69 (anti-gB) and anti-VP16 (anti- α TIF).

35 Figure 5 shows the effect of exposure to and dilution of

-7-

CTC-96 on the accumulation of α RNAs in HSV-1 infected cells. Vero cell monolayers were either mock-infected (M) or infected with HSV-1 at a MOI of 5 in the presence (+) or absence (-) of 50 μ g/ml of CTC-96. Additionally on some samples, CTC-96 was diluted (D). Total cell RNA was prepared at either 2 or 4 hpi. The α 4 and α 27 mRNAs were amplified by RT-PCR in the presence of [γ - 32 P]dCTP under linear amplification conditions (see Materials and Methods). The amplimers were electrophoretically separated through polyacrylamide gels and visualized by autoradiography. The left hand most lane represents molecular markers. Each condition was performed in duplicate.

Figure 6 shows HSV-1 DNA replication in the presence of CTC-96. Vero cell monolayers were either mock-infected (M) or infected with HSV-1 in the presence (+) or absence (-) of 50 μ g/ml of CTC-96 at a MOI of 5. CTC-96 was added to the infected cells at the indicated hours postinfection (Hpi). Total cell DNAs were harvested at 1 hpi (A), 9 hpi (B) or 24 hpi (C). Ten fold dilutions (1X, 0.1X and 0.01X) of the DNAs were slot blotted onto nylon membranes, hybridized with a α - 32 P labeled probe complementary to the α 4 gene and visualized by autoradiography.

Figure 7 shows HSV-1 DNA localization in the presence of CTC-96. (A) Vero cell monolayers were infected with HSV-1 at a MOI of 10 in the presence (+) or absence (-) of 50 μ g/ml of CTC-96, or 100 μ g/ml of cycloheximide (CHX). Infected cells were harvested at either 5 or 60 min postinfection (mpi). Nuclear and cytoplasmic fractions were prepared (see Materials and Methods) and slot blotted onto nylon membranes. Virus DNAs were hybridized with a α - 32 P labeled probe complementary to the α 4 gene and visualized by autoradiography. (B) Vero cell monolayers were either mock-infected (M) or infected with 3H-labeled HSV-1 (INF) in the presence (+) and absence (-) of 50 μ g/ml of CTC-96.

-8-

Figure 8 shows the effect of CTC-96 on virus entry visualized by α TIF immunofluorescence. HSV-1 was adsorbed to Vero cell monolayers in the presence or absence of 50 μ g/ml of CTC-96 at a MOI of 100 for 45 min at 4°C on ice. Infected monolayers were warmed to 37°C for 5 min (A, B), 30 min (C, D) and 60 min (E, F) after which they were fixed and permeabilized. Immunodetection of α TIF was performed using the rabbit polyclonal antibody, anti-VP16, and the goat anti-rabbit IgG antibody conjugated to FITC as the primary and secondary antibodies, respectively. Immunofluorescence was visualized using confocal microscopy. Each image is the combined average of 1 μ m Z-series.

Figure 9 shows the effect of CTC-96 on virus entry visualized by fluorescence dequenching fusion assays. Octadecyl rhodamine B (R_{18}) labeled HSV-1 was adsorbed to Vero cells (MOI=100) at 4°C on ice for 45 min in the presence(B, D, F) or absence (A, C, E) of 50 μ g/ml of CTC-96. Infected cells were warmed to 37°C for 5 min (A, B), 10 min (C, D) and 40 min (E, F). After fixation, the amount of fluorescence dequenching of R_{18} upon fusion of the virion envelope with the plasma membrane was visualized using confocal microscopy. The data are represented as overlays of the fluorescent R_{18} image and the phase contrast image of the same field of cells. Arrows indicate HSV-1 aggregates. (G) The amount of fluorescence dequenching in the presence and absence of 50 μ g/ml of CTC-96 was quantitated using flow cytometry. The fusion assay was performed as described above except that after fixation the cells were scraped into PBS and analyzed using a fluorescence activated cell sorter (FACStar). The FACStar was calibrated prior to sample loading using rhodamine calibrate beads.

Figure 10 shows the cell-cell spread of HSV-1 in the presence of CTC-96. (A) (B)

-9-

Figure 11 shows the effect of CTC-96 on endocytosis of a fluid-phase marker.

Figure 12 shows virus DNA replication in the presence of CTC-
5 96. Vero cells were infected at an moi of in the presence
or absence of 50 μ g/ml of CTC96. At 1 and 9 hr pi cells were
harvested and analyzed for the amount of virus DNA. Each
sample was done in duplicate and two concentrations of DNA
were applied to the filter for analysis by Southern blot
10 hybridization. The relative intensity of each band was
determined using a Molecular Dynamics phosphorimager.

Figure 13 shows the effect of Temporal Addition of CTC96 on
15 HSV DNA Replication. Vero cell monolayers were infected at
an moi of 5 with HSV-1 and treated at the indicated time with
50 μ g/ml of CTC-96. At either 1 or 24 hr pi cells were
harvested and assayed for the amount of virus DNA that was
present in each sample. Three serial 10-fold dilutions of
each sample were applied to the filters prior to
20 hybridization with 32 P-labeled probe.

Figure 14 shows HSV-1 Specified Protein Accumulation in Cells
Infected in the present of CTC-96. Vero cells infected at an
moi of 5 with HSV-1 in the presence (0 hr pi or 1 hr pi) or
25 absence (none) of drug were harvested at the indicated times
post infection and examined by Western blot with antibodies
specific for immediate early (ICP's 0 and 27), early gB and
late (α TIF) proteins.

30 Figure 15 shows RNA accumulation in cells infected with HSV-
1. A stock of HSV-1 was either treated with CTC-96 for 10 and
then used to infect Vero cells (+) at an moi of 5, treated and
then diluted prior to infection(+) or infected with untreated
virus (-). The extreme left lane contains DNA markers and
35 the lanes indicated by an M contain RNA extracted from mock
infected cells. At the indicated times pi infected cell RNAs

-10-

were prepared and examined for the presence of transcripts derived from the α 27 or α 4 genes by 20 cycles of RT-PCR using primers specific for transcripts originating from these genes under conditions where amplification was linear. Images were 5 rendered by Phosphorimaging using a Molecular Dynamics StormImager.

Figure 16 shows the fractionation of virus DNA. Cells infected with HSV-1 in the absence (None) or presence of 10 either CTC-96 ($50\mu\text{g}/\text{ml}$) or cycloheximide ($100\mu\text{g}/\text{ml}$) were harvested at the indicated times post infection and fractionated into nuclear and cytosolic compartments by treatment with detergent. DNAs were extracted from each 15 fraction, transferred to a nitrocellulose membrane using a slot blot apparatus and hybridized to a ^{32}P -labeled probe to detect virus DNA.

Figure 17 shows a visualization of virus entry. HSV-1 (moi=100) was allowed to adsorb to cells at 4°C for 1 hr in 20 the presence or absence of $50\mu\text{g}/\text{ml}$ of CTC-96. The temperature was then raised to 37°C and entry was monitored by immunohistochemical analysis using antibody to α -TIF to follow the fate of infecting virus. α -TIF-antibody complexes were visualized by confocal microscopy.

25


Figure 18 shows visualization of the effect of CTC-96 on cells infected with VZV. Very few cells were positive for VZV in the presence of CTC-96.

-11-

Detailed Description of the Invention

The subject invention provides a method of treating a subject infected with a virus or a method of preventing viral infection of a subject comprising administering to the 5 subject an anti-viral effective amount of a compound having the structure shown as formula I below:

Formula I



wherein R¹, R², R³, and R⁴ may be the same or different and 20 may be an alkyl group, a phenyl group or a substituted derivative of a phenyl group;

wherein R⁵ may be hydrogen, a halide, an alkoxide group, an 25 alkyl group or OH;

wherein L and L' may be the same or different and may be NH₃, an imidazole, a substituted derivative of an imidazole, such as 2-methylimidazole; and

wherein Q⁻ is a soluble, pharmaceutically acceptable negative 30 ion.

The compounds are also described in U.S. Patent No. 35 5,756,491, the content of which is incorporated herein by reference.

-15-

conventional carrier medium is incompatible with the anti-viral compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the 5 pharmaceutical composition, its use is contemplated to be within the scope of this invention.

Pharmaceutical organic or inorganic solid or liquid carrier media suitable for enteral or parenteral administration can 10 be used to make up the composition. Gelatine, lactose, starch, magnesium, stearate, talc, vegetable and animal fats and oils, gum, polyalkylene glycol, or other known carriers for medicaments may all be suitable as carrier media.

15 Unit dosage forms for oral administration include, for example, tablets, troches, powders, pills, granules and capsules. For such dosage forms, additives, for example, a binder such as gum arabic, gelatin, sorbitol, tragacanth, polyvinyl pyrrolidone, polyvinyl alcohol, hydroxypropyl 20 methyl cellulose, methyl cellulose, crystalline cellulose or sodium carboxymethyl cellulose, an excipient such as lactose, sugar, saccharose, sucrose, mannitol, corn starch, potassium phosphate, sorbitol or crystalline cellulose, a lubricant such as magnesium stearate, talc, polyethylene glycol or 25 silica, and a disintegrant such as potato starch, low substitution hydroxypropyl cellulose, calcium carboxymethyl cellulose or sodium carboxymethyl starch, may be used alone or in suitable combination. Soft capsules may contain a vehicle commonly employed, such as vegetable oil, 30 polyethylene glycol or glycerol, or an oily suspending agent given hereinafter, a solution, or a wetting agent such as a surfactant.

Liquid formulations may be, for example, an aqueous or oily 35 suspension, solution, syrup or elixir, or a dried product including a freeze-dried substance which can be dissolved in

-14-

Although compounds described herein can be administered to any subject which is susceptible to viral infection, the compounds are intended for the treatment of mammalian hosts, and especially humans. While the subject may be a human
5 being, any mammal susceptible to the viral infection, such as domestic fowls, pigs, horses and the like may be treated with the compound.

The compound may be formulated into an antiviral
10 pharmaceutical compositions, which comprises one or more of the compounds of formula I above, as the active ingredient in combination with a pharmaceutically acceptable carrier medium or auxiliary agent.

15 These formulations may be prepared in accordance with the respective conventional methods. The composition may be prepared in various forms for administration, including tablets, caplets, pills, aerosol, an inhalant, a solution, a powder, a capsule or an ointment or can be filled in
20 suitable containers, such as capsules, or, in the case of suspensions, filled into bottles. The compounds of the invention may be administered orally, parenterally, such as by intramuscular injection, intraperitoneal injection, aerosol, intravenous infusion or the like, depending on the
25 severity of the infection being treated.

As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's
30 Pharmaceutical Sciences, Fifteenth Edition, E.W. Martin (Mack Publishing Co., Easton, PA, 1975) discloses various carriers
35 used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any

-13-

In a further embodiment the invention provides a method for treating a subject infected with by a non-enveloped virus comprising a anti-nonenveloped virus effective amount of the compound of Formula I.

5

In yet a further embodiment the invention provides a method for preventing infection of a subject by a non-enveloped virus comprising administering to the subject an anti-nonenveloped virus effective amount of the compound of
10 Formula I.

The non-enveloped virus may be but is not limited to poliovirus and adenovirus.

15 The anti-enveloped virus effective amount may be an anti-HSV-1 effective amount, an anti-varicella-zoster virus effective amount, an anti-vesicular stomatitis virus effective amount, or an anti-influenza virus effective amount.

20

The anti-nonenveloped virus effective amount may be an anti-poliovirus effective amount or an anti-adenovirus effective amount.

25 In a further embodiment, the subject invention provides a method of sterilizing tools and equipment, such as surgical and other medical tools and equipment.


30 In yet a further embodiment, the subject invention provides a method of sterilizing a room comprising spraying in the room a fine mist comprising the compound of Formula I.

35 In another embodiment, the subject invention provides a method of sterilizing air comprising dispersing in the air a fine mist comprising the compound of Formula I.

-12-

In a preferred embodiment each of R¹, R², R³, and R⁴ is CH₃; R⁵ is H or Cl; L=L' = imidazole or 2-methylimidazole; and Q⁻ is Cl⁻ or Br⁻. In the most preferred embodiment the compound has the structure of Formula II below, also also referred to 5 herein as "CTC-96":

Formula II



wherein L=L' = 2-methylimidazole.

20 In another embodiment the invention provides a method for treating a subject infected with an enveloped virus comprising administering to the subject an anti-enveloped virus effective amount of the compound of Formula I.

25 In yet another embodiment the invention provides a method for preventing infection of a subject by an enveloped virus comprising administering to the subject an anti-enveloped virus effective amount of the compound of Formula I.

30 The enveloped virus may be but is not limited to HSV-1, varicella-zoster virus, vesicular stomatitis virus, and influenza virus. In the case of influenza, the influenza viruses can be classified into three types, namely A, B and
35 C depending on the serum types of nucleoproteins and membranous proteins.

-16-

water or in other suitable vehicle at the time of its application. For such liquid formulations, additives, for example, a suspending agent such as methyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose,
5 hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, tragacanth, gelatin or sodium alginate, an emulsifier such as lecithin, sorbitan, a fatty acid ester, gum arabic or tragacanth, a lubricant such as a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene
10 fatty acid ester, hydrogenated castor oil, sesami oil, soybean oil, propylene glycol, polyethylene glycol or ethyl alcohol, an antiseptic such as methyl p-hydroxybenzoate, propyl p-hydroxybenzoate or sorbic acid, and a sweetener such as a syrup, sucrose, sorbitol or mannitol, may be used alone
15 or in suitable combination.

As the base for a drug for intrarectal administration, an oily base such as cacao butter, witepsol, or triglyceride, or a water-soluble base such as glycerol, glycerogelatin or
20 macrogol, may be employed. As additives for an injection solution, a solubilizer such as polyoxyethylene, hardened castor oil or sodiumbenzoate, an isotonic agent such as glucose, sodium chloride or glycerol, and a stabilizer such as sodium sulfite, anhydrous sodium sulfite, sodium
25 metahydrogen sulfite or glycerol, may be used alone or in suitable combination.

For the administration to a respiratory organ such as the nose or bronchus, a formulation such as an aerosol, an
30 inhalant, a solution, a powder, a capsule or an ointment, may be employed. In the case of an aerosol, it may be an oily aerosol formulation comprising a nonionic surfactant such as Alacel or Span 80, an amphoteric surfactant such as lecithin or a dispersant such as oleyl alcohol, a propellant such as
35 butane or Freon.RTM., or an aqueous aerosol formulation comprising an isotonic agent such as physiological saline,

-17-

a phosphate buffer or an acetate buffer and purified water or distilled water for injection. In the case of a solution, for example, polyethylene glycol, sorbitol, polysorbate or physiological saline may be used as the carrier for the 5 formulation. In the case of a powder, for example, crystalline cellulose, α -cellulose, sodium crosslinked carboxymethyl cellulose, hydroxypropyl cellulose, carboxymethyl starch or amirose may be used as the carrier for the formulation. In the case of an ointment, for example, 10 polyethylene glycol, hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose or hydroxypropyl cellulose may be used as the carrier for the formulation.

The antiviral agent of the present invention may take a form 15 which is applied to the mucous membrane of the oral cavity or nose so that the active ingredient is gradually released after the application. As the base to be used for such formulation, a cellulose ether such as methyl cellulose, ethyl cellulose, propyl cellulose, hydroxyethyl cellulose, 20 carboxyethyl cellulose or hydroxypropyl cellulose, as well as polyacrylic acid or carboxyvinyl polymer, may be mentioned.

The antiviral agent of the present invention may also take 25 the form of an antiviral spray.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and 30 results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

-18-

EXPERIMENTAL DETAILS

Materials and Methods

Cells and Viruses.

5 Vero cells were maintained in 5% bovine calf serum (BCS; Hyclone Laboratories Inc., Logan, UT) Dulbecco's minimal essential medium (DMEM; Gibco BRL, Grand Island, NY). HeLa, MDCK and A549 cells were maintained in 10% fetal bovine serum (FBS; Hyclone Laboratories Inc., Logan, UT) DMEM. HeLa cells
10 were maintained in suspension in 7% BCS Joklik's medium (Specialty Media, Lavallette, NJ) and monolayers in 5% BCS DMEM. All media contained 100U of penicillin per ml and 100 μ g of streptomycin per ml (Gibco BRL).

15 The wild-type virus strains used were: HSV-1 Glasgow strain 17 (9); poliovirus strain Pl Mahoney (provided by V. Racaniello, Columbia University, NY); adenovirus serotype 2 (Ad2) and Ad-CMV-null (both provided by C. S. H. Young, Columbia University, NY); varicella-zoster virus (VZV) strain
20 Ellen (provided by P. Annuziato and A. Gershon, Columbia University, NY); influenza virus strain PR8 (provided by Mount Sinai School of Medicine, NY); and vesicular stomatitis virus (VSV) strain Indiana (provided by V. Racaniello, Columbia University, NY).

25

HSV-1 preparation.

(i) Cell-associated HSV-1. Vero cell monolayers were infected at low multiplicities of infection (MOIs) and incubated at 37°C for 2-3 days. Infected cell were scraped
30 into the media and spun down. The infected cell pellet was washed with phosphate-buffered saline (PBS; 2.7mM KCl, 1.2mM KH₂PO₄, 138mM NaCl, 8.1mM Na₂HPO₄•7H₂O), resuspended in 1% BCS DMEM and freeze (-80°C)-thawed (37°C) five times. The virus was then titrated on Vero cells. Unless otherwise
35 indicated cell-associated HSV-1(17) was used for infection.

-19-

(ii) Partially purified HSV-1. Vero cells were infected at a low MOI and incubated at 37°C for 2-3 days. Infected cells were scraped into the media, spun at 913 x g for 5 min at 4°C, washed with PBS and spun again. The infected cell pellet was resuspended in PBS-ABC (PBS containing 5mM MgCl₂ and 7mM CaCl₂) and incubated on ice for 15 min. The suspension was dounced (15 strokes) in a sterile Wheaton dounce homogenizer using pestle B. The nuclei was spun out at 3,015 x g for 5min at 4°C. The virions in the supernatant were spun down at 20,384 x g for 75-90 min at 4°C and the virus pellet was resuspended in PBS-ABC-ICS-glu (PBS-ABC containing 1% inactivated BCS and 0.1% glucose). The virus was pelleted through a 3ml sucrose cushion (30% sucrose in 50mM NaCl, 10mM Tris pH 7.8) for 2h at 187,813 x g in a Beckman SW41 rotor (6, 26). The virus was resuspended in PBS-ABS-ICS-glu and then titrated on Vero cells.

(iii) ³H labeled HSV-1. Vero cells were infected at a MOI of 1. Ten µCi of [6-³H]-thymidine (19.2 Ci/mmol; NEN Life Sciences Products, Boston, MA) per ml of media was added to the infected cells at 2 hours postinfection (hpi) and incubated at 37°C for 2 days. ³H labeled virions were partially purified from the infected cells as described above.

25

(iv) Octadecyl rhodamine B (R18) labeled HSV-1. Fluorescence dequenching fusion assays were performed as previously described with slight modifications (38, 39, 70). Partially purified HSV-1 was labeled by addition of 14 nmol of R18 (also known as octadecyl rhodamine B; Molecular Probes Inc., Eugene, OR) in ethanol per 425µg of virus protein and incubated at room temperature for 1h in the dark with gentle mixing. Free R18 was removed from R18 labeled virions using a Sephadex G75 column. R18 labeled HSV-1 was eluted off the column with PBS in 1 ml fractions and each fraction was titrated on Vero cells. Labeled virus elutes in the void

-20-

volume while free R18 remains on the column. It is important to note that concentrations of R18 above 32.9 nmol per μ g of virus protein is toxic to HSV-1 (Drs. J. Marcelletti and L. Pope, personal communications).

5

(v) Syn- virus purification. Vero cells were infected at a low MOI. Syncytia (syn-) containing plaques were isolated and plaque purified 2 more times. Cell-associated syn- virus (vJS17syn-) was prepared as described above.

10

Plaque Formation in the Presence of Drug.

To determine what concentration of drug was required to reduce plaque formation by herpes simplex virus monolayer cultures of Vero cells were infected with 10^2 , 10^3 and 10^4 pfu 15 of virus in the presence of varying concentrations of CTC-96 and the number of surviving plaques was determined. The results of this experiment showed that there was a sharp cutoff in drug sensitivity. At $50\mu\text{g}/\text{ml}$ plaques formation was reduced by greater than 99% whereas at $25\mu\text{g}/\text{ml}$ by only 30%.
20 We note that at $50\mu\text{g}/\text{ml}$ of drug the cell monolayer was severely affected after two days of incubation.

The long term effects of short term exposure to drug were assayed by treating virus suspensions with drug for 1 min. 25 and then diluting the virus-drug solution in medium so that the final concentration of drug is $<1\mu\text{g}/\text{ml}$. Under this condition we noted that some virus survived treatment (~50%). The result of one of these experiments are presented below in Table 1. It would appear that even transitory exposure 30 to drug results in a marked decrease in plaque formation.

-21-

Table 1. Effects of Exposure and Dilution on Virus Plaque Formation

	Initial [Drug] $\mu\text{g}/\text{ml}$	Final [Drug] $\mu\text{g}/\text{ml}$	No. of Plaques
5	0	0	107
	50	50	0
	100	100	0
	0.016	0.016	114
10	50	0.0083	46
	100	0.0016	23

Plaque assays.

(i) HSV-1. Vero cell monolayers were infected with 102, 103 and 104 plaque forming units (pfu) of HSV-1 in the presence of various concentrations of CTC-96 (REDOX Pharmaceutical Corporation, Greenvale, NY). After 1h adsorption at 37°C in 1% BCS DMEM with and without CTC-96, infected cell monolayers were overlaid with methylcellulose overlay media (1.5% methylcellulose, 1% BCS, 100U of penicillin per ml, and 100 μg of streptomycin per ml in DMEM) containing the indicated amount of CTC-96. Plates were incubated at 37°C for several days and fixed with methanol. The plates were stained with 0.1% crystal violet and plaques counted.

(ii) Poliovirus. HeLa cell monolayers were infected with dilutions of poliovirus. Dilutions were performed in 0.2% BCS PBS with or without 50 $\mu\text{g}/\text{ml}$ CTC-96. Two hundred μl of the diluted virus was added to each monolayer and incubated at 37°C for 1h. After adsorption, infected monolayers were overlaid with top agar overlay media (4% top agar, 100U penicillin per ml, 100 μg of streptomycin per ml, and 5% BCS in DMEM) with or without 50 $\mu\text{g}/\text{ml}$ CTC-96. After incubation at 37°C for 2 days, infected monolayers were fixed with 10% TCA and stained with 0.1% crystal violet.

-22-

(iii) VSV. Virus was diluted and adsorbed as described above for poliovirus. After adsorption, infected Vero cell monolayers were overlaid with methylcellulose overlay media and incubated at 37°C for 2 days. Monolayers were fixed and 5 stained as stated above for HSV-1.

(iv) Influenza virus. Virus was diluted in PBS(+) /BA/PS [PBS containing 0.68mM CaCl₂, 0.49mM MgCl₂, 0.4% bovine albumin (ICN Biomedicals, Inc., Costa Mesa, CA), 100U of 10 penicillin per ml and 100µg of streptomycin per ml] with and without 50µg/ml CTC-96. One hundred µl of each dilution was added to MDCK cell monolayers and adsorbed for 30 min at 37°C. Infected monolayers were overlaid with overlay media [0.2% bovine albumin, 2µg/ml 1:250 trypsin (Gibco BRL), 0.02% 15 DEAE dextran, 1.2% purified agar (Oxoid LTD., Basingstoke, Hampshire, England), 100U of penicillin per ml and 100µg of streptomycin per ml in DMEM] with and without 50µg/ml CTC-96 and incubated at 37°C for 3 days. Infected cells were fixed and stained as describe above for poliovirus.

20

Adsorption assay.

Adsorption of HSV-1 and detection of bound versus free virus was performed as described previously (6). Vero cell monolayers were infected with 3H labeled HSV-1 at a MOI of 25 100.

Western blot analysis.

Vero cell monolayers were infected at a MOI of 5 in the presence or absence of 50µg/ml CTC-96. Protein preparation 30 and western blot analysis were performed as previously described (54). Briefly, at the indicated times the infected cells were collected by centrifugation, resuspended in 1.5x SDS-PAGE sample buffer, and boiled for 10 min. The proteins 35 were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose membranes. Immunodetection of proteins was performed using the following antibodies: ICP0,

-23-

rabbit polyclonal antibody CLU7 (54); ICP27, rabbit polyclonal antibody CLU38 (54); glycoprotein B (gB), rabbit polyclonal antibody R69 (provided by T. Kristie, National Institute of Allergy and Infectious Diseases) [Zhang, et al. 5 1991]; and TIF, rabbit polyclonal antibody anti-VP16 (Clontech Laboratories Inc., Palo Alto, CA). The secondary antibodies used were goat anti-rabbit and goat anti-mouse IgG conjugated to horseradish peroxidase (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, MD). Immunoblots were 10 developed as previously described (55).

RT-PCR.

Vero cell monolayers were either mock infected or infected. The accumulation of α 4 and α 27 mRNAs from infected cells was 15 determined as previously described [Lium and Silverstein 1997] by coupled reverse transcription (RT) and polymerase chain reaction (PCR) using the commercial kit, EZ rTth RNA PCR kit (Perkin-Elmer) as specified by the manufacturer with modifications. The primers used during RT were 4-2 and 20 ICP27-L-RT [Lium and Silverstein 1997]. Following RT, secondary primers were added for PCR (4-1 and ICP27-U-RT) (55). These primers result in amplification of a 100 basepair (bp) fragment and a 220 bp fragment from the α 4 and α 27 genes, respectively.

25

DNA replication.

(i) DNA preparation. Vero cells infected with MOI of 5 were infected and maintained in the presence and absence of 50 μ g/ml CTC-96. Infected cells were harvested by freezing 30 (-80°C) at the indicated times postinfection. Total infected cell DNA was extracted as described (54).

(ii) Slot blot analysis. Slot blot analysis was performed as previously described (55). Briefly, equal 35 amounts of nuclear or cytoplasmic infected cell DNAs were blotted onto GeneScreen Plus using a MINIFOLD II Slot Blot

-24-

System (Schleicher and Schuell, Keene, NH) and cross-linked with a Stratalinker 2400 (Stratagene, La Jolla, CA) using UV-irradiation. A 4.5kB SalI-DdeI fragment from the $\alpha 4$ gene of HSV-1 which had been labeled with [α -32P]dCTP (NEN Life Sciences Products, Boston, MA) by random priming (Boehringer Mannheim, Indianapolis, IN) was hybridized to the nuclear and cytoplasmic DNAs and washed as specified by the manufacturer. Bands were visualized using autoradiography.

10 DNA Replication in the Presence of Drug.

A series of experiments were initiated to determine the point in the replication cycle where CTC-96 acts. Our first study examined the effects of drug on replication of virus DNA. Cells were infected at an moi of 5 in the presence of the 15 absence of drug and harvested by trypsinization at 1 and 9 hr post infection. Virus DNA was extracted from cells by selective salt precipitation and the amount of virus-specific DNA was assayed after transfer to a nitrocellulose membrane by Southern blot hybridization using a phosphorimager to 20 quantitate signal. The results of a typical analysis are shown in Fig. 12. The results of this analysis suggest that there are equivalent amount of virus DNA associated with infected cells at 1 hr post infection. However, virus DNA replicates vigorously only in the sample that does not 25 contain drug. While there is barely a two-fold increase in the accumulation of virus DNA in drug treated samples the amount of virus DNA in the untreated infected sample increases by about 50-fold. We conclude that there is little if any virus DNA replication in cells infected with HSV in 30 the presence of CTC-96.

It was conceivable that the drug blocks DNA replication, therefore we asked if addition of CTC-96 at various times post infection had an effect on virus DNA replication. Cells 35 were infected and at various intervals drug was added and left on the infected cell cultures until 24 hr pi. At this

-25-

time samples were harvested and DNA extracted and analyzed as described above. Analysis of the Southern blot reveals a graded temporal response to the addition of drug such that there is increasingly more virus DNA replication as drug is
5 added at later times post infection. By 12 hr post infection the bulk of DNA replication is complete as there is only a small difference between the hybridization signal generated in an untreated 24 hr sample when compared with a sample treated at 12 hr and analyzed at 24 hr post infection (Fig.
10 13).

Fractionation of virus DNA.

Vero cells were infected at a MOI of 10 in the presence and absence of 50 μ g/ml CTC-96 or 100 μ g/ml cycloheximide.
15 Preparation of nuclear and cytoplasmic fractions were performed as described (69). Briefly, infected monolayers were washed with PBS, 1.75ml of reticulocyte standard buffer (RSB; 10mM Tris, pH 7.4, 10mM NaCl, and 1.5mM MgCl₂) was added to each plate and incubated on ice for 5 min. To each plate, 50 μ l of 20% (v/v) Triton X-100 and 200 μ l of 10X MAGIK solution [10% (v/v) Tween 40 (Sigma, St. Louis, MO) and 5% (w/v) deoxycholate] was added. Cells were scraped off the plates and then homogenized by 4 passes through a 25 gauge needle. The suspension was pelleted at 3,000 x g at 4°C. The
20 supernatant was saved as the cytoplasmic fraction to which each of the following was added to the indicated final concentrations: 0.5% (w/v) SDS, 10mM EDTA, 100mM NaCl and 200 μ g/ml proteinase K. The nuclear pellet was resuspended in RSB containing Triton X-100, MAGIK, SDS, NaCl, EDTA and
25 proteinase K to the final concentrations stated above. The cytoplasmic and nuclear fractions were then incubated at 56°C overnight, phenol:chloroform extracted and ethanol precipitated. Slot blot analysis was performed as previously described above for DNA replication and by Liim and
30 Silverstein, 1997 (55).
35

-26-

In situ hybridization.

Vero cells seeded on two chambered slides were infected with partially purified ³H-labeled HSV-1 in the presence and absence of 50 μ g/ml CTC-96. At various times post-infection
5 the cells were fixed in methanol:acetic acid (3:1).

Virus entry assays.

(i) α TIF immunofluorescence. Vero cell monolayers seeded on cover slips were infected with a MOI of 100 on ice at 4°C
10 for 45 min. Pre-warmed media (37°C) was added to each plate, incubated at 37°C for the indicated times and washed twice with ice cold PBS on ice. The infected cells were fixed in 3.7% formaldehyde in PBS for 30 min at room temperature and washed with PBS. The fixed monolayers were permeabilized in
15 -20°C acetone at -20°C for 10 min. Cells were washed with water and then PBS. Fixed cells were incubated in 10% normal goat serum (NGS; Roche, Indianapolis, IN) in 0.1% Tween 20 in PBS (PBST) for 20 min at RT and washed twice with PBST. Cover slips were then incubated in PBST containing 1% NGS and
20 1:200 polyclonal antibody anti-VP16 antibody (Clontech Laboratories, Inc.) for 30 min and washed 6 times with PBST. The infected cell monolayers were then incubated in PBST containing 1% NGS and 1:200 goat anti-rabbit IgG antibody conjugated to fluorescein isothiocyanate (FITC; Kirkegaard
25 and Perry Laboratories, Inc.) for 30 min and washed 6 times with PBST. The cover slips were then mounted on slides in gel/mount solution (Biomedica, Fisher, Springfield, NJ) and viewed with a 100X lens of a Zeiss LSM 4100 confocal laser scanning system attached to a Zeiss Axiovert 100TV inverted microscope. Each image is the average of 1 μ m Z series.
30

(ii) Fluorescence dequenching fusion assay - Microscopy. The R18 labeled HSV-1 (see above) fusion assay was performed as described above for α TIF immunofluorescence with the exception that after formaldehyde fixation the fixed
35 monolayers were wet mounted on slides in 50mM DABCO (Sigma) in PBS and viewed using the 100X lens of a Zeiss LSM 4100

-27-

confocal laser scanning system attached to a Zeiss Axiovert 100TV inverted microscope. All incubation steps were performed in the dark. Each immunofluorescence image is the average of 1 μm Z series. Figure 9A shows the 5 immunofluorescence image overlaid on the phase contrast image of the same field of cells.

(iii) Fluorescence dequenching fusion assay - Flow cytometry.

(iv) Electron microscopy. Vero cell monolayers were 10 infected with a MOI of 100 on ice at 4°C for 45 min with and without 50 $\mu\text{g}/\text{ml}$ CTC-96. Pre-warmed media (37°C) was added and incubated at 37°C for the indicated times. Plates were washed twice with ice cold PBS on ice, fixed for 1.5h at room temperature and washed with 0.1mM cacodylate buffer.

15

Cell-cell spread.

(i) Immunofluorescence. Vero cell monolayers were seeded onto cover slips and infected at a MOI of 0.01 in 1% BCS DMEM. At 6hpi, the media was replaced with 1% BSC DMEM 20 containing 50 $\mu\text{g}/\text{ml}$ CTC-96 and 1:200 anti-HSV antibody (in order to neutralize extracellular virus). At 20hpi the infected monolayers were washed with PBS, fixed, permeabilized and immunodetected as described above for α TIF. The primary antibodies used were rabbit polyclonal CLU38 25 (anti-ICP27) and (anti-ICP8). The secondary antibodies were goat anti-rabbit and goat anti-mouse conjugated to rhodamine and FITC (Kirkegaard and Perry Laboratories, Inc.), respectively.

30 (ii) Syncytia formation. Vero cell monolayers were infected with vJS17syn- at a MOI of 0.01. At 6hpi, the media was replaced with methylcellulose overlay media with and without 50 $\mu\text{g}/\text{ml}$ CTC-96. The ability of the virus to form syncytia was then monitored after 2 days at 37°C.

35

Fluorescence focus assay.

-28-

A549 or 293 cell monolayers were infected with Ad2 or Ad-CMV-null at 0.1 fluorescence focus units (FFUs) per cell for 2h in 2% BCS DMEM in the presence and absence of 50 μ g/ml CTC-96. At 29h postinfection the plates were washed twice
5 with PBS and fixed with methanol for 4 min at room temperature. Cells were washed twice with PBS, incubated in 500 μ l 1:100 rabbit polyclonal anti-adenovirus serum in PBS for 30 min at room temperature and washed with PBS. Plates were then incubated in 500 μ l 1:40 goat anti-rabbit IgG
10 conjugated FITC in PBS. Foci were visualized using a Leitz Dialux microscope with an optical system for the selective visualization of FITC and then counted.

Immunohistochemistry.

15 Helf cell monolayers seeded on two chambered slides were infected with 20 μ l cell-associated VZV in 1% FBS DMEM in the presence and absence of 50 μ g/ml CTC-96. At 28h postinfection, the slides were washed twice with PBS, fixed in 3.7% formaldehyde in PBS for 30 min at room temperature, and
20 washed again. The infected cells were washed twice with Tris-buffered saline (TBS) and incubated at -20°C in -20°C acetone for 10 min. Slides were washed twice with TBS, blocked with 1% goat serum (Sigma, St. Louis, MO) in TBS for 20 min at room temperature, and incubated in 200 μ l 1:200
25 rabbit polyclonal anti-ORF 29 in 1% goat serum TBS for 30 min at room temperature. The slides were washed three times with TBS for 5 min each and then incubated with 200 μ l 1:200 goat anti-rabbit IgG conjugated horseradish? peroxidase (Kirkegaard and Perry Laboratories Inc.) in 1% goat serum TBS
30 for 30 min at room temperature. Slides were washed three times with TBS for 5 min each. The peroxidase was developed for 5 min using the commercial kit, Alkaline Phosphatase Substrate Kit III (Vector Laboratories Inc., Burlingame, CA) according to the manufacturer's directions and then washed
35 several times with water. The slides were viewed with a Leitz Dialux microscope.

-29-

Endocytosis assay. Vero cells seeded on cover slips were incubated at 37°C in 5% BCS DMEM with and without 50 μ g/ml CTC-96 for various times. The media was then replaced with 5% DMEM containing 1:200 Lysotracker (Molecular Probes, Inc.) with and without 50 μ g/ml CTC-96. The cells were incubated at 37°C for the indicated times, washed on ice with ice cold PBS and fixed at room temperature in 3.7% formaldehyde in PBS for 30 min. The cover slips were washed several times with PBS, mounted in Biomedica gel/mount (Fisher) and viewed with a Leitz Dialux microscope with an optical system for the selective visualization of rhodamine.

Accumulation of Virus-Specified Proteins in the Presence of Drug. Failure to efficiently replicate virus DNA could result from a specific block of replication per se or because virus-specified gene expression is affected by drug. To address this issue cells were infected with HSV-1 at an moi of 5, 50 μ g/ml of drug was either added at time 0, 1hr pi or not added and at intervals post infection the infected cells were harvested and proteins were extracted and assayed for the presence of virus specified polypeptides by Western blot. Using antibodies that recognize proteins from each of the three kinetic classes we were able to demonstrate that there is little if any synthesis of either ICP0 or ICP27, two immediate early gene products. As a consequence of the failure to detect immediate early protein synthesis there was no measurable accumulation of either gB, an early protein, or α -TIF, a late protein (Fig. 14). In contrast, addition of the drug after one hr of infection has only a small effect on the accumulation of virus-specified proteins from each of the three major kinetic classes (Fig. 14). This finding is what might have been expected from the DNA replication data which demonstrated that replication proceeded in cells where drug was added after the initiation of virus infection. The residual reactivity with α -TIF in the sample treated at T=0 results from protein associated with the infecting virions.

-30-

There is no increase in the accumulation of this protein during the course of infection. It is not possible to exclude the possibility that virus never enters these cells and that the α -TIF that is detected results from cell 5 associated virus.

The failure to detect virus specified polypeptides of any kinetic class in cells infected in the presence of CTC96 led us to ask if virus transcripts accumulated under these 10 conditions. Accordingly, virus was incubated with 50 μ g/ml of drug for 10 min and then either washed out by dilution and used to infect cells or used directly to infect cells. At 2 and 4 hr post infection cells were harvested and total infected cell RNA was prepared for analysis by RT-PCR for the 15 presence of transcripts from the α 4 and α 27 genes. The results of this analysis reveal that there is no accumulation of these virus-specified RNA's when cells are infected in the presence of drug (Fig. 15). When these studies are carried out to as long as 8 hr pi there is still no detectable 20 accumulation of virus-specified transcripts (data not shown). A small amount of immediate early gene RNA is detected in cells infected with virus exposed to the drug for only 10 min. (Fig 15). These findings suggest that the virus fails to initiate its transcription program.

25

Introduction of Virus DNA in the Presence of Drug
To further address the nature of the block to expression of virus genetic information in cells infected with HSV-1 in the presence of CTC-96 we asked if virus DNA entered the nucleus 30 of cells infected in the presence of drug, as a control cells were infected by virus and harvested after 5 min or infected with virus in the presence of cycloheximide which arrests protein synthesis but still permits virus entry and transport of the genome to the nucleus. Following harvest, the nuclei 35 and cytosol were fractionated by detergent treatment and virus DNA was extracted from each compartment for analysis

-31-

by Southern blot hybridization. The results of this analysis are presented in Fig. 16. After 5 min very little virus DNA is detected in the nucleus or cytoplasm of untreated cells. By 1 hr pi there is abundant virus DNA in the nucleus of 5 cells infected with HSV-1 either in the presence or absence of protein synthesis. In contrast there is still very little detectable virus DNA in either fraction prepared from cells infected in the presence of drug. The residual signal generated from the Nuclear compartment in infected cells 10 harvested at 5 min and in cells infected in the presence of CTC-96 probably results from adventitious sticking of virus particles to cell membranes despite the detergent treatment used to fractionate the cells. This result, in concert with the previous studies, suggests that virus does not enter 15 cells in the presence of drug.

Entry of HSV-1 into Cells Treated with CTC-96.

There are several approaches to assessing the ability of virus to adsorb and enter a cell. Perhaps the simplest and 20 most direct is to visualize the transfer of virion-associated proteins from the outside of the cell to its inside. The α -gene transcriptional inducing factor (α -TIF) is a tegument protein that is an integral part of the virion which ultimately ends up in the nucleus shortly after infection to 25 aid in the initiation of transcription of immediate early genes from the genome. It is possible to directly visualize this transfer by immunofluorescence. Accordingly, virus was adsorbed to cells in the presence or absence of drug at 4°C for 1hr and then shifted to 37°C and harvested at 5, 30 and 30 60 min pi. The samples were fixed and stained with antibody specific for α -TIF. Shown in Fig. 17 are the results of this analysis. It is clear from this study that at 5 min after shift up to 37°C virus has attached to the periphery of the cells and that there appears to be less virus bound 35 to the drug treated cells. At 30 min post shift the virus has entered the cells and can be found in the cytoplasm and

-32-

the nucleus of the cell infected in the absence of drug. By contrast there is no evidence for virus entering the cell when drug is present. After 60 the nuclear signal begins to become more disperse and it becomes clear that there is no 5 evidence for α -TIF in cells infected in the presence of drug.

CTC-96 was also tested in accordance with procedures described above for activity against other enveloped viruses 10 (Examples 1-3 below) as well as against non-enveloped viruses (Examples 4-5 below).

EXAMPLE 1 - VZV Infection

Cells

15 Half cells were plated at 5×10^5 cells per chamber on 2 chambred slides in 10% FBS DMEM. When cells were a tightly packed monolayer they were infected.

Infection

20 Cells were infected with cell associated VZV \Rightarrow 20 λ stock in 1% FBS DMEM (2ml) +/- CTC96. (Vero cells were also infected but in 1% BCS DMEM and incubated @ 37°C for ~30h.)

25 Fixation (without removing chambers)

Slides were washed 2x w/PBS
fixed with 2ml/chamber of 3.7% formaldehyde in PBS
for 30 min @ RT
washed 2x w/PBS
30 stored @4°C in PBS

Immunohistochemistry

washed 2x w/1x TBS
removed chambers & gaskets
35 incubated 10 min @ -20°C in - 20°C 100% acetone
washed 2x w/1x TBS

-33-

incub. 20 min in 200λ/chamber area 1% goat serum in TBS
poured off block soln.
Incub. 30 min. In 200λ 1:200 1°AB in 1% goat serum in
TBS
5 used either rabbit α or F29 or rabbit α or F14
washed 3x 5 min each in TBS
incub. 30 min in 200λ 1:200 goat α rabbit-phosphatase in
1% goat serum in TBS
washed 3x 5 min each in TBS
10 developed with ABC kit -200λ soln. For 5 min.
Washed several times w/H₂O
mounted cover slips on slides w/gel/mount \rightarrow microscope

The results are shown in Figure 18. Very few cells were
15 positive in the presence of CTC-96.

EXAMPLE 2 - VSV Infection

Cells

20 Vero cells were plated @ 1x10⁶ cells/well on 6 wellled
plates in 10% BCS DMEM

Infection

used VSV from V. Racamiello at 6.5x10⁸ pfu/ml

25 undil. \rightarrow -2 \rightarrow -4 \rightarrow -5 \rightarrow -6 \rightarrow -7
stock (1:100) (1:100) (1:10) (1:10) (1:10)

diluted in 0.2% BLSPBS +/- 50μg/ml CTC96
30 added 100_ of -5, -6, -7 dilutions to cells
incubated @ 37°C, in - shaking every 5 min
overlaid w/3ml 3% methyl cellulose in 1% BLSDMEM
incubated @37°C

35 Fixation

\sim 24hpi \rightarrow nice sited plaques

-34-

shook off methylcellulose
fixed ~45min in MeOH
stained ~45 min in 0.1% crystal violet

5 The cells treated with CTC-96 (50 μ g/ml) showed 100% inhibition.

Table 2 - VSV Infection of cells - CTC-9 and + CTC-96.

	-5	-6	-7
-CTC	553	43	4
-CTC	553	37	5
+CTC	0	0	0
+CTC	0	0	0

EXAMPLE 3 - Influenza Infection

Initial trials with influenza virus encountered problems with growing of the cells and infection of the cells. Nonetheless, upon addition of CTC-96 a positive virus inhibitory effect was observed. The magnitude of the effect was not quantifiable.

Subsequent studies show that CTC-96 is effective against influenza virus infection. A study using MDCK cells shows that CTC-96 is effective against influenza virus infection.

30 **EXAMPLE 4A - Adenovirus Infection**

Cells

293T cells were plated on 35mm dishes. Cells should be @ 5x10⁶ cells/plate.

35 **Infection**

-35-

293T Cells were infected with AdCMV-null @ moi=0.1
(i.e. 0.1FFU/cell)

Virus was absorbed @ 37°C for 2h, rocking every 15 min

5 in 200λ abs volume

virus was diluted in D2 media +/- 50μg/ml CTC96

D2 = 2% serum DMEM

Plates were overlaid with 2.5ml D2 +/- 50μg/ml CTC96

10 and incub. @ 37°C for 28h (total)

(Media was added drowise to plate because 293T cells
are easily popped off plate)

15 2 plates of cells were incub. In D2 media (no virus) and
2 plates of cells were incub. In D2 media +50μg/ml
CTC96 (to see cytotoxic effect of drug on 293T cells)

Fixation

20 28 hpi - plates were washed 2x w/25ml PBS
added 90% MiOH (2.5ml) - RT 4min
washed 2x w/2.5ml PBS - 4min each
stored @ 4°C in 2.5ml PBS o.n.

25 Plates containing 293T cells + or - 50μg/lm CTC96 were
examined

-CTC-96 - cells appeared normal (<5% rounded)

+CTC96 - at least 50% rounded (CPE)

30 Staining

Incub. RT, 30 min in 500λ R α Ad antiserum (diluted 1:00
in PBS)

washed 2x w/25ml PBS

35 Incub. RT 30 min in 500λ G α R-FITL (1:40 in PBS)

washed 2x w/25ml PBS

-36-

added 500 λ PBS
 stored in dark @ 4°C

5 plates containing 293T cells + or - CTC96 were examined
 - CTC96 → appeared normal but very dense (<5% rounded)
 + CTC96 → 50% of cells were off of plate the remaining
 50% were rounded up (CPE)

Table 3 - Cells with adenovirus but without CTC-96.

10 Plate #1 Plate #2

Grid	# pos. cells		Grid	# pos. Cells
1	27		1	29
2	17		2	19
3	30		3	80
15 4	20		4	25
5	21		5	21
6	17			

20 Cells with adenovirus and with CTC-96 (50 μ g/ml) showed NO
FOCI ON EITHER PLATE. Thus, CTC-96 inhibits adenovirus.

EXAMPLE 4B - Adenovirus infection

25 Cells

A549s were plated on 35mm dishes at 8x10⁵ cell/plate in
 10% FBS DMEM

30 Infection

Cells had not reached confluence yet (~80-90%)
 Thus, this experiment performed in duplicate.

Ad2 stock \Rightarrow 1.3x10⁷ FFU/ml

for moi = 0.1 need 1x10⁵ FFU/plate assuming 1x10⁶ cells

-37-

need 1×10^5 FFU/200λ

added $19.25\mu\text{l}$ stock to $50\mu\text{l}$ total of each respective media (+/- 0, 5, 25 or $50\mu\text{g}/\text{ml}$ CTC96)

5

Added 200λ of abs. vol. to each plate

Incubated @ 37°C for 2h, rocking occassionally

One plate → added media alone (no virus, no CTC96)

One plate → added $50\mu\text{g}/\text{ml}$ CTC96 media only (no virus)

10

The media used was 2% BCS DMEM

After 2h-added 3ml of each respective media

15

Incubated @ 37°C for 28h(total)

Adenovirus

20	CTC-96 ($\mu\text{g}/\text{ml}$)	Percent inhibition					
		0%		18%		64%	
		0	0	25	25	50	50
25	Plate #	1	2	1	2	1	2
	Field #1/36	4	2	3	0/2	0/3	2/0
	2/37	2	1	1	3/1	2/0	0/2
	3/38	7	7	0	3/0	0/1	0/1
	4/39	4	3	6	4/4	1/4	2/2
	5/40	4	6	0	1/2	0/2	0/1
30	6/41	5	1	3	1/5	1/0	2/0
	7/42	5	6	3	3/3	1/1	1/0
	8/43	4	5	4	2/3	1/1	2/1
	9/44	6	8	6	0/2	0/1	1/2
	10/45	4	3	9	1	1/0	0/3

-38-

	11/46	2	2	3	4	1/3	0/0
	12/47	3	5	1	0	2/4	5
	13/48	3	5	1	4	1	2
	14/49	4	2	4	3	0	2
5	15/50	3	3	6	2	1	3
	16	2	6	6	1	2	2
	17	3	7	5	2	2	0
	18	4	4	5	0	2	2
	19	2	6	6	4	2	4
10	20	6	3	9	3	1	1
	21	4	4	5	2	2	3
	22	3	3	2	2	0	1
	23	5	6	1	2	3	3
	24	11	6	3	5	2	0
15	25	2	4	2	3	2	2
	26	6	108	8	6	2	3
	27	108	1	102	3	1	3
	28	1	108/	1	2	4	0
			25=4				
			.3				
	29	108/		102/	4	1	1
		26=4		26=3			
		.2		.9			
20	30				6	2	2
	31				3	5	2
	32				3	4	1
	33				1	1	1
	34				2	3	2
25	35				2	0	3
					109	73	70

-39-

					109/ ?=3. 1	73/4 7=1. 6	70/4 6=1. 5
--	--	--	--	--	-------------------	-------------------	-------------------

5 EXAMPLE 5 - Poliovirus Infection

Cells

Hela cells (grown from spinner culture) were plated on 6 welled plated @ 1×10^6 cells/well in 10% BCS DMEM

10

Infection

Polovirus strain P1 Mahoney was used to infect cells (essentially titrated virus).

15

stock was 1×10^9 pfu/ml

serial dilutions in 0.2% BCS PBS +/- 50 μ g/ml CTC96 were performed (-1, -2, -3, -4, -5, -6, -7, -8)

Last 3 dilutions were used to infect cells 100 λ abs. Vol. Was used

20

incub. @ 37°C for 1h shaking every 10 min

overlay media was made:

melted agar 8% top a jar in microwave then equilibrated to 42°C (should be 45°C)

25

Also equilibrated 10% bcs 2Xdmem TO 42°C

immediately prior to use DMEM & agar was mixed 1:1

Added 2 ml over lay media to each well (Did not add drug to overlay media)

did not remove abs. vol. from wells

30

Incub. Plates @37°C for 2 days

Plaques Assay-Polio

once plaques were visible by eye - fixed/stained plates

-40-

fixed plates by adding TCA to each plate incubated at RT for 10min

removed agar plugs → added crystal violet for n 10min
5 mounted plaques

	<u>-6</u>	<u>-7</u>	<u>-8</u>	dilutions
-CTC96	152	16	0	$\rightarrow 1.46 \times 10^9$ pfu/ml
	140	25	0	
10	+CTC96	91	10	0
		80	9	0

Recovered 58% of -CTC-96.

Therefore, 42% inhibition.

15 This trial was run in duplicate and the second run results were obtained as follows:

POLIOVIRUS PLAQUE ASSAY

Cells

20 Hela cells were plated on 6 welled plates @ 1×10^6 cells/well on 10% BCS DMEM

Infection

Infected Hela with Polio P1/Mahoney (In 0.2% BLS PBS)

25 stock ($\sim 1 \times 10^9$ pfo/ml)

1:10 → -1 → -2 → -3 → -4 → -5 → (-6 → -7)

1:10 (in 0.2% BCS PBS +50 μ g/ml CTC96)

→ -1 → -2 → -3 → -4 → -5 → (-6 → -7)

30 ↘ (in 0.2% BCS +100 μ g/ml CTC96)

→ → -2 → -3 → -4 → -5 → (-6 → -7)

took 100 λ abs. vol. from -6 & -7 dilutions and plated in duplicate (dilutions were not done in duplicate rather the dilutions were infected twice)

-41-

Incub. 1h 37°C, rocking every 10-15min
made overlay media (1:1 8% top a jar 42°C, 2x10%BCS
DMEM 42°C)

5 added drug (CTC-96) to media immediately prior to
mixing with a jar
once made overlay was immediately added to each well
(2ml) containing the respective drug concentration.

10 Incubate 2 days @37°C
Fix/Stain
fixed 10min RT in TCA: stained 10min in crystal violet

15 -6 -7 -6 -7
no drug TMTC 45 50 μ g/ml 165 18 42% inhibition
no drug TMTC 36 50 μ g/ml * 16
 100 μ g/ml cells were dead
 100 μ g/ml cells were dead

20

Results

HSV-1 is inhibited by CTC-96 in tissue culture. The anti-herpetic activity of the CTC complexes against the herpes simplex viruses has been known for many years (3, 22, 25, 88). The majority of these studies have been *in vivo* protocols which addressed the efficacy of the CTC series of compounds against herpesviruses (3, 22, 25, 88). Comparison of several CTC complexes showed that CTC-96 was the most potent inhibitor of HSV-1 in tissue culture and in the rabbit eye model (3). However, the mechanism(s) by which these drugs inhibit HSV has not been studied.

CTC-96 inhibition of HSV-1 in tissue culture (Fig. 2) (3) was non-linear as 25 μ g/ml of CTC-96 prevented the formation of approximately 30% of HSV-1 plaques compared to the no drug

-42-

control (Fig. 2A), while $\geq 50\mu\text{g}/\text{ml}$ of CTC-96 completely inhibited plaque formation (Fig. 2). This non-linear inhibitory profile may suggest that $25\mu\text{g}/\text{ml}$ is not sufficient to saturate its target. Furthermore, CTC-96 must be present throughout infection as dilution of the drug after adsorption of the virus only partially inhibited the formation of plaques (Fig. 2B). However, it was unclear whether this partial blockage was the result of a lag in initiation of infection or whether the drug affected an aspect of the virus or cellular machinery necessary for efficient production of HSV-1 plaques.

In order to address whether CTC-96 directly effects the virions and/or cell monolayer in a irreversible manner virus was incubated with $50\mu\text{g}/\text{ml}$ of CTC-96 for 30 min on ice or at room temperature. Prior exposure of the virus to the drug had no effect on plaque formation providing CTC-96 was diluted significantly prior to adsorption (data not shown). However, prior incubation of Vero cell monolayers with $50\mu\text{g}/\text{ml}$ of CTC-96 conferred partial resistance to HSV-1 (data not shown). This resistance decreased as a function of time after drug removal (data not shown). These results suggest that CTC-96 does not irreversibly alter the infectivity of HSV-1 virions, but may perhaps effect a cellular factor(s) involved in supporting HSV-1 production. It is not clear whether the drug is metabolized within the cell, but may be possible as resistance to HSV-1 disappears the longer the cells have not been exposed to drug. However, addition of CTC-96 is only required at the onset of infection which may suggest contrary to the previous hypothesis that CTC-96 is not metabolized. The hypothesis that CTC-96 is acting upon a cellular mechanism(s) is further supported by the observation that prolonged exposure to $\geq 50\mu\text{g}/\text{ml}$ CTC-96 has cytotoxic effects upon Vero cell monolayers (data not shown) (3).

35

CTC-96 has no effect on attachment of HSV-1 to Vero cell

-43-

monolayers. CTC-96 inhibits HSV-1 plaque formation. Yet, it is not apparent by what mechanism(s) it achieves this inhibition. A prerequisite for HSV-1 infection is binding of the virion envelope glycoproteins, glycoprotein C (gC) and 5 glycoprotein D (gD), to their cell surface receptors glycosoaminoglycan heparan sulfate (36, 37, 50, 78, 82, 83, 94) and herpes virus entry mediator (HVEM) (63), respectively. Several drugs effective in inhibiting HSV-1 infection have recently been shown to block attachment of HSV 10 virions to their cellular receptors (1). Therefore, the possibility exists that CTC-96 inhibits virion binding to the plasma membrane. We asked whether HSV-1 was able to bind to Vero cells in the presence of 50 μ g/ml of CTC-96. HSV-1, grown in the presence of [6-³H]-thymidine, was adsorbed to Vero 15 cell monolayers at 4°C on ice and the amount of radioactivity that remained cell-associated after several washes was measured. The presence of 50 μ g/ml of CTC-96 had no effect on the ability of ³H labeled HSV-1 to bind to Vero cells (Fig. 3). Thus, we reasoned that CTC-96 must inhibit a 20 post-attachment phase of infection.

Virus proteins do not accumulate when CTC-96 is present during infection. The expression of HSV-1 genes and their gene products occurs in a temporal fashion and are classified 25 into three kinetic classes (α , β , and γ) (41, 42). The production of proteins from all of these classes is required to produce infectious progeny (41, 42). To determine whether the inhibitory action of CTC-96 on plaque formation results in a delay in the temporal order of HSV-1 infection, we 30 examined the accumulation of virus proteins in the presence of 50 μ g/ml of CTC-96. CTC-96 prevented the accumulation of gene products from all kinetic classes when present from the initiation of infection (Fig. 3). The appearance of bands reactive to α TIF and gB antibodies when CTC-96 is present 35 from the onset of infection does not result from de novo synthesis of these β/γ proteins (Fig. 3) (35, 40), but rather

-44-

these bands represent the proteins associated with the infecting virions (Fig. 3B as both α TIF and gB are found within HSV-1 virions (12, 58-60, 96). Yet, when CTC-96 is added subsequent to the initiation of infection, there is
5 little or no effect on the accumulation of the α gene products, ICP0 and ICP27 (Fig. 3), nor on the β/γ gene products, α TIF and gB (Fig. 3). Thus, once the cascade of protein synthesis is initiated CTC-96 has no significant effect on virus protein accumulation (Fig. 4). These results
10 suggest that CTC-96 exerts its inhibitory effects on the HSV-1 life cycle after attachment, but at or prior to the synthesis of the α gene products.

A mRNAs do not accumulate unless CTC-96 is present throughout
15 infection. The cascade of HSV-1 gene expression does not require de novo protein synthesis (31, 85, 89) and is initiated by the virion-associated protein, α TIF (11, 71). The first genes turned on by α TIF are the α genes (34, 67). The gene products of two of these genes, α 4 and α 27, are
20 essential for the subsequent expression of β and γ genes (21, 24, 61, 72, 75). Therefore, we examined whether the α 4 and α 27 mRNAs were able to accumulate in the presence of CTC-96. In fact, neither the accumulation of α 4 nor α 27 mRNAs were detectable when CTC-96 was present from the onset of
25 infection (Fig. 4). However, despite a short recovery period α 4 and α 27 mRNAs began to accumulate if CTC-96 was removed after infection was initiated (Fig. 4) suggesting that the inhibitory effect(s) of CTC-96 are not irreversible. The lack of α mRNA accumulation in the presence of drug suggests that
30 CTC-96 inhibition occurs at or prior to mRNA synthesis.

Temporal prevention of virus DNA replication by CTC-96. In order to further elucidate the stage at which CTC-96 inhibits the HSV-1 life cycle we examined the ability of infected
35 cells to produce virus DNA in the presence and absence of CTC-96. At 1, 9 and 24hpi, total cell DNAs were prepared,

-45-

blotted and hybridized with radiolabeled DNA specific for the $\alpha 4$ gene. When CTC-96 was present from the onset of infection and infected cell DNA was harvested at 1hpi, no detectable difference between the amount of virus specified DNA was 5 observed (Fig. 6A). However, when the infected DNAs were harvested at 9 (Fig. 6B) or 24 (Fig. 6C) hpi there was a dramatic increase in virus DNA replication in the absence of CTC-96 compared to samples infected in the presence of 50 μ g/ml of CTC-96 (Fig. 6). Regardless of the harvest time, 10 there is no significant difference in the amount of virus specified DNA in the presence of CTC-96 (Fig. 6).

Previously we showed that CTC-96 needed to be present from the initiation of infection in order to completely inhibit 15 virus protein (Fig. 4) and mRNA (Fig. 5) accumulation as well as plaque formation (Fig. 2B). Therefore, we examined whether this observation could be extended to virus DNA replication. When CTC-96 was added to infected cells at later and later times postinfection the amount of virus DNA replication 20 increased (Fig. 6C). However, there was a lag in the amount of virus DNA that accumulated as the amount of DNA present at 24hpi when CTC-96 was added at 4hpi (Fig. 6C) appeared equivalent to DNA harvested at 9hpi in the total absence of CTC-96 (Fig. 6B). These data suggest that like virus protein 25 and mRNA accumulation, virus DNA replication is not inhibited by CTC-96. In addition, there is a temporal requirement for the inhibitory effects of CTC-96.

Virus DNA does not translocate to the nucleus in the presence 30 of CTC-96. In order for virus specified DNA, mRNA and protein synthesis to occur, the virus genome must first be translocated into the nucleus. Since inhibition of the virus processes studied so far required addition of CTC-96 at the onset of infection, we hypothesized that the drug may inhibit 35 nuclear localization of virus genomic DNA. The observed temporal requirement for CTC-96 addition would support such

-46-

a hypothesis as addition after infection initiation may allow for virus DNA translocation. Furthermore, the observed lag after CTC-96 addition after infection onset may result from inhibition of further virus DNA translocation. To test this 5 hypothesis, we used biochemical and microscopic techniques to examine whether HSV-1 DNA was able to enter the nucleus in the presence of CTC-96. Nuclear and cytoplasmic fractions of infected cell DNA were prepared, blotted and hybridized to a radiolabeled α 4 probe. By 5 min postinfection virus DNA 10 was found in the nuclear fraction (Fig. 7A). However, as virus DNA accumulated in the nuclear fraction by 1hpi in the absence of CTC-96, no significant increase in nuclear associated HSV-1 specific DNA was observed in the presence of CTC-96 (Fig. 7A). Inhibition of HSV-1 DNA translocation 15 was not the result of protein synthesis inhibition as cycloheximide had no effect on the amount of virus DNA associated with the nuclear fraction compared to the no drug control (Fig. 7A).

20 We further confirmed these biochemical data by visually observing the localization of virus DNA. Vero cells were infected with 3 H-thymidine labeled HSV-1 in the presence and absence of CTC-96. Autoradiographic emulsions, which results 25 in the accumulation of silver grains where radioactivity is present, were used to enhance the 3 H signal from the HSV-1 DNA. CTC-96 prevented the nuclear accumulation of 3 H labeled HSV-1 DNA (Fig. 7B) while cells infected in the absence of CTC-96 accumulated virus DNA in the nucleus (Fig. 7B). Furthermore, in the presence of CTC-96 HSV-1 DNA do not 30 display a peri-nuclear localization pattern (Fig. 7B). These results suggest that not only does CTC-96 inhibit nuclear localization of virus DNA, but it also prevents cytoplasmic transport of HSV-1 genomic DNA from the plasma membrane to the nuclear envelope.

35

α TIF nuclear translocation does not occur when CTC-96 is

-47-

present. Upon HSV-1 entry/uncoating the capsid containing the virus genome moves through the cytoplasm to the nuclear pores (81). The tegument protein, α TIF, also undergoes translocation to the nucleus (48). In addition, α TIF appears 5 to remain associated with the virus capsid in the cytoplasm (95). Thus, in order to address our hypothesis that CTC-96 inhibits cytoplasmic transport of virus genomic DNA, we determined whether α TIF translocation is also inhibited by CTC-96. Indirect immunofluorescence analysis of α TIF showed 10 that α TIF normally localizes to the nucleus by 30 min postinfection (Fig. 8). This nuclear accumulation is not the result of de novo α TIF synthesis as α TIF protein synthesis did not occur until 2hpi under these same conditions (data not shown). Yet, when CTC-96 was present α TIF was unable to 15 accumulate in the nucleus by 1hpi (Fig. 8). Taken together these results suggest the CTC-96 prevents the transport of capsid associated proteins and cargo. Accordingly, CTC-96 must either inhibit virus cytoplasmic transport or HSV-1 entry/uncoating.

20 CTC-96 inhibits HSV-1 infection in tissue culture by preventing fusion of the virus envelope with the plasma membrane. As we previously showed that CTC-96 did not effect HSV-1 attachment to Vero cell monolayers (Fig. 3), we next 25 examined whether bound virus was able to enter the cell in the presence of CTC-96. In order to accomplish this we utilized a fluorescence dequenching fusion assay developed for influenza virus (57). This assay is performed by labeling the virus envelope with a lipophilic fluorescent 30 dye, octadecyl rhodamine B (also known as R₁₈). The central principle of this assay is that under the local concentrations in the virus envelope R₁₈ self quenches. However, upon fusion of the virus envelope with the plasma 35 membrane the virus associated R₁₈ diffuses laterally in the plasma membrane resulting in fluorescence dequenching. This dequenching can be visually and quantitatively measured by

-48-

an increase in fluorescence intensity (57). Although, this assay was developed for influenza virus it has successfully extended for use with other enveloped viruses (4, 8, 23, 38, 39, 47, 57, 62, 70, 80). Using confocal microscopy and flow cytometry we examined whether CTC-96 was able to inhibit HSV-1 entry. R_{18} labeled HSV-1 was adsorbed on ice at 4°C to Vero cell monolayers which allowed virus to bind, but essentially inhibited fusion of the virus envelope with the plasma membrane until the infected monolayers were warmed to 37°C. Addition of CTC-96 prevented HSV-1 fusion to the cell (Fig. 9). By 40 min post-warming there was a dramatic increase in fluorescence in the absence of CTC-96 as seen by confocal imaging (Fig. 9, compare panels A, C and E). However, CTC-96 significantly damped the amount of fluorescence dequenching (Fig. 9, panels B, D and F). These results were further confirmed by quantitative flow cytometry (Fig. 9G).

Some dequenching was observed in the presence of CTC-96 (Fig. 9). In order to determine if this is an artifact of the assay or if it indicated that HSV-1 was able to fuse to the cell but at a reduced rate, we further examined virus entry using electron microscopic analysis (Fig. 10). Thus, CTC-96 inhibits HSV-1 by preventing virus entry. While CTC-96 appears to inhibit a variety of viruses, it appears to be most effective against enveloped viruses. Table 4 below summarizes the effect of CTC-96 on infection by various viruses.

Table 4. Summary of the effect of CTC-96 on infection by various viruses.

<u>Virus (Strain/ Serotype)</u>	<u>Cells</u>	<u>% Inhibition*</u>	<u>Enveloped</u>	<u>Entry via Endocytosis</u>
HSV-1 (17) ^{a†}	Vero	100	Yes	Partial

-49-

VZV (Ellen) ^b	HeIff	100	Yes	
VSV (Indiana) ^a	Vero	100	Yes	
Influenza (PR8) ^a	MDCK	?	Yes	Yes
Ad-CMV-null ^c	293T A549	100 ND	No	Yes
Adenovirus (2) ^c	293T A549	ND 36	No	Yes
Poliovirus (P1/Mahoney) ^a	HeLa	40	No	

10

* Percent inhibition in the presence of 50µg/ml of CTC-96.

† Summary of Figure 2.

a Data obtained by plaque assay (see Material and Methods).

b Data obtained by immunohistochemistry (see Material and Methods).

c Data obtained by fluorescence focus assay (see Materials and Methods).

20 ND: not determined because AD-CMV-null cannot productively infect A549.

Comparison of CTC-96 with other drugs.

One attractive target for drugs the initial stage of infection (i.e., entry/uncoating). Several drugs exist which inhibit HSV infection by blocking attachment or fusion of the virus envelope with the plasma membrane. Heparin, a polysulfonate complex, can block attachment through competitive binding for heparan sulfate proteoglycans.

30 Sumarin, a derivative of urea, is also able to block HSV attachment, but unlike heparin is able to inhibit cell to cell spread of the virus as well. Another drug under study is n-docosanol, a saturated primary alcohol. Unlike heparin and sumarin, n-docosanol does not inhibit binding, but rather

-50-

fusion of the virus envelope with the cell's plasma membrane. As a result it is also effective against other enveloped viruses which do not require endocytosis for entry. However, one exception to this is influenza A virus. Although it requires the acidic environment of endocytic organelles to accomplish entry it can be inhibited by n-docosanol.

Conclusions

Several complexes in the CTC series of cobalt chelates display in vitro and in vivo activity against the herpes simplex viruses, HSV-1 and 2. The compound CTC-96 exhibits the most potent inhibitory effect against HSV-1 keratitis in rabbits. The experiments described here analyze the toxicity of CTC-96 on HSV-1 infection in Vero cells and determine how CTC-96 inhibits the virus life cycle. There is a sharp cutoff in drug sensitivity where plaque formation is reduced by >99% at 50 μ g/mL and only 30% at 25 μ g/mL. CTC-96 at 50 μ g/mL appears to have no effect on adsorption of virions to Vero cell monolayers. Western blot analysis shows that CTC-96 prevents synthesis of all kinetic classes of virus proteins. RT-PCR also shows that CTC-96 inhibits α 4 and α 27 gene expression. Furthermore, CTC-96 inhibits DNA replication. Inhibition of nuclear accumulation of virus DNA and virion-associated α TIF in the presence of CTC-96 suggests that CTC-96 prevents nuclear entry of capsid-associated proteins and DNA cargo. Yet, immunofluorescence and in situ hybridization experiments do not reveal peri-nuclear accumulation of α TIF or HSV-1 DNA. We show that CTC-96 inhibits the fusion of the virion envelope with the plasma membrane as determined by microscopy and flow cytometric fusion assays. Taken together these data suggest that CTC-96 inhibits HSV-1 infection at the point of entry and/or uncoating. In addition, the anti-viral effects of CTC-96 are not specific to HSV-1, as it also inhibits varicella-zoster virus, vesicular stomatitis virus, influenza virus, poliovirus and adenovirus infections.

-51-

The data shows that that CTC-96 is virucidal in nature. It's primary mechanism of action is to prevent virus infection by inhibiting entry. The action of the drug is rapid and irreversible, occurring in less than 10 min. Future studies
5 will focus on the target for inhibition by CTC-96 and identification of the step in entry that is blocked. The approaches for these studies will include isolation of mutants and characterization of the proteins and their domains that interact with the drug.

10

Discussion

The mechanism by which CTC-96 inhibits HSV-1 infection in tissue culture was studied by using a variety of assays that probe the virus processes which are essential for productive
15 infection. Consistent with a previous report (3), we found that concentrations of CTC-96 >50 µg/ml completely inhibited plaque formation (Fig. 2A). Incubation of Vero cells with 50 µg/ml of CTC-96 for several days did however result in cytotoxicity (data not shown). Prior incubation of cell
20 monolayers or HSV-1 with CTC-96 conferred partial resistance (data not shown) and slightly reduced the infectivity of HSV-1 (Fig. 2B), respectively. CTC-96 had no effect on adsorption of HSV-1 to Vero cell monolayers (Fig. 3). However, it did completely inhibit macromolecular synthesis as no virus-specific DNA (Fig. 6), RNA (Fig. 4) or proteins (Fig. 5) were detected in cells infected in the presence of drug. CTC-96 also prevented nuclear accumulation of virion-associated αTIF (Fig. 8) and HSV-1 DNA (Fig. 7). Using a fluorescence dequenching assay, we demonstrated that the fusion of the
25 virus envelope with the cell membrane was inhibited in the presence of CTC-96 (Fig. 9). Therefore, unlike the antiviral drugs currently approved for treatment of HSV-1, CTC-96 prevents entry of virus into cells.

30 35 We have now elucidated the point in the virus life cycle at

-52-

which CTC-96 exerts its inhibitory effects. However, our data do not provide insight into the exact mechanism of inhibition of fusion. CTC-96 may alter the structure of proteins required for membrane fusion by preventing the 5 conformational change of virus glycoproteins and/or cellular receptors which are believed to be important for fusion initiation and completion. Alternatively, CTC-96 may induce a conformation not conducive for membrane fusion. CTC compounds have been shown in vitro to selectively unfold 10 proteins (7). Accordingly, if the cell and virus fusogenic proteins require precise functional conformations, CTC-96 may inhibit their function by preventing protein-protein and/or protein-membrane interactions required for membrane fusion.

15 Several virus glycoproteins which play a role in the fusion of the virus envelope with the plasma membrane are also involved in cell-to-cell spread and cell fusion. Therefore, to further elucidate the inhibitory mechanism of CTC-96 we examined whether virus was able to spread to adjacent cells.

20 When CTC-96 was added at 8hpi, HSV-1 infected cells were unable to form multi-celled foci (Fig. 9). Thus, cell-to-cell spread is inhibited whether virus infects adjacent cells by direct contact of the plasma membranes or via the interstitial space. Furthermore, a syncytia forming virus was 25 unable to form syncytia when CTC-96 was added at 1 or 10 hpi (data not shown). Therefore, the inhibition of the fusion processes involved in HSV-1 infection by CTC-96 suggests that there is a general mechanism of fusion shared by these processes.

30 The CTC compounds were shown to irreversibly bind to and specifically inhibit a DNA binding Zn-finger, Sp1, in vitro (56). Based on this observation it was postulated that the antiviral activity of the CTC compounds could inhibit HIV-1 35 by binding to Zn-finger containing nucleocapsid proteins as well as to Sp1 which may be important for HIV-1 virus

-53-

transcription (56). Furthermore, the cytotoxic effects of CTC-96 may result from in vivo inhibition of cellular and viral Zn-finger containing proteins. The HSV-1 immediate-early gene promoters contain numerous Sp1 sites (46) which might provide secondary targets for CTC-96 if it enters cells. However, these hypotheses seem unlikely in light of our results. It is plausible that CTC-96 does not efficiently enter cells considering the temporal requirement for addition of CTC-96 on virus inhibition. This is further supported by our observation that there is only a negligible drop in virus titers when CTC-96 is added at 16hpi and virus is harvested 4 hours later (data not shown). Hence, CTC-96 does not appear to act intracellularly. Therefore, based on our observations of the inhibitory effects of CTC-96 on fusion, CTC-96 may be harmful to cells in tissue culture by preventing global and/or local membrane dynamics, a vital cellular process. Despite its toxic effect on cells in culture, 50 µg/ml of CTC-96 does not appear to be toxic in animal models (3, 22, 25, 88).

We have as of yet been unable to isolate CTC-96 resistant viruses. This suggests that either CTC-96 targets one or more essential cellular or virus components or it effects a global process such as membrane dynamics. If membrane fluidity is altered by CTC-96 it would need to be reversible as the partial resistance conferred by preincubation with CTC-96 disappears upon dilution of the drug. Thus, inhibition by CTC-96 on virus entry and its effect on cell viability has implications for a global inhibitory mechanism on the coalescence of membranes.

The appearance of ACV-resistant herpesviruses in patients significantly intensified the effort to develop drugs which inhibit an aspect of the virus life cycle different from the current nucleoside analogs used in treatment against the

-54-

herpesviruses. One attractive target for anti-herpetic drugs is the initial stage of infection (i.e., entry/uncoating). Several drugs exist which inhibit HSV infection by blocking attachment or fusion of the virus envelope with the plasma membrane. Heparin, a polysulfonate complex, can block attachment through competitive binding for heparan sulfate proteoglycans (1). Sumarin, a derivative of urea, is also able to block HSV attachment, but unlike heparin it is also able to inhibit cell-to-cell spread (1). Another drug currently being studied is n-docosanol, a saturated primary alcohol. Unlike heparin and sumarin, n-docosanol does not inhibit virus binding, but rather fusion of the virus envelope with the cell's plasma membrane (70). As a result, it has a broad spectrum and is also effective against other enveloped viruses including influenza A virus (70).

In view of a previous report that CTC-96 inhibits infection by other enveloped herpesviruses (88), it is likely that a similar inhibitory mechanism(s) acts upon these viruses. Consistent with previous reports (88), we observed inhibition of VZV plaque formation by CTC-96 (data not shown). It would be interesting to determine if CTC-96 is also able to inhibit enveloped viruses outside the herpesvirus family. Despite differences in the fusogenic apparatus at the atomic level, it has been proposed that several enveloped viruses share an analogous process in membrane fusion (33, 43, 49, 90). Analysis of the efficacy of CTC-96 against other viruses could reveal a common mechanism(s) of membrane fusion between viruses and cells. CTC-96 may provide a new avenue for inhibiting highly mutagenic viral agents as membrane fusion is an essential infectious process for enveloped viruses.

-55-

References

1. Aguilar, J. S., M. Rice, and E. K. Wagner. 1999. The polysulfonated compound suramin blocks adsorption and lateral diffusion of herpes simplex virus type-1 in Vero cells. *Virology*. 258:141-151.
2. Alrabiah, F. A., and S. L. Sacks. 1996. New antiherpesvirus agents: their targets and therapeutic potential. *Drugs*. 52:17-32.
3. Asbell, P. A., S. P. Epstein, J. A. Wallace, D. Epstein, C. C. Stewart, and R. M. Burger. 1998. Efficacy of cobalt chelates in the rabbit eye model for epithelial herpetic keratitis. *Cornea*. 17:550-557.
4. Bagai, S., and R. A. Lamb. 1995. Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 5 of Newcastle disease virus. *J. Virol.* 69:6712-6719.
5. Balfour, H. H. 1999. Antiviral drugs. *N. Engl. J. Med.* 340:1255-1268.
6. Banfield, B. W., Y. Leduc, L. Esford, K. Schubert, and F. Tufaro. 1995. Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry pathway. *J. Virol.* 69:3290-3298.
7. Blum, O., A. Haiek, D. Cwikel, Z. Dori, T. Meade, and G. H. B. Gray. 1998. Isolation of a myoglobin molten globule by selective cobalt(III)-induced unfolding. *Proc. Natl. Acad. Sci. USA*. 95:6659-6662.
8. Blumenthal, R., A. Bali-Puri, A. Walter, D. Covell, and O. Eidelman. 1987. pH-dependent fusion of vesicular stomatitis virus with Vero cells. *J. Biol. Chem.* 262:13614-13619.
9. Brown, S., D. A. Ritchie, and J. H. Subak-Sharpe. 1973. Genetic studies with herpes simplex virus type 1. The

-56-

isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. *J. Gen. Virol.* 18:329-346.

5 10. Cai, W., B. Gu, and S. Person. 1988. Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. *J. Virol.* 62:2596-2604.

11. Campbell, M. E. M., J. W. Palfreyman, and C. M. Preston. 1984. Identification of herpes simplex virus 10 DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. *J. Mol. Biol.* 180:1-19.

12. Claesson-Welsh, L., and P. G. Spear. 1986. Oligomerization of herpes simplex virus glycoprotein B. *J. Virol.* 60:803-806.

13. Coen, D. M., and P. A. Schaffer. 1980. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. *Proc. Natl. Acad. Sci. USA.* 77:2265-2269.

20 14. Collins, P., B. A. Larder, N. M. Oliver, S. Kemp, I. W. Smith, and G. Darby. 1989. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. *J. Gen. Virol.* 70:375-382.

25 15. Corey, L., and P. Spear. 1986. Infections with herpes simplex viruses. *N. Eng. J. Med.* 314:686-691.

16. Corey, L., and P. Spear. 1986. Infections with herpes simplex viruses. *N. Eng. J. Med.* 314:749-757.

17. Crumpacker, C. S. 1989. Molecular targets of antiviral therapy. *N. Engl. J. Med.* 321:163-172.

30 18. Darby, G., H. J. Field, and S. A. Salisbury. 1981. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. *Nature.* 289:81-83.

35 19. Davis-Poynter, N., S. Bell, T. Minson, and H. Browne. 1994. Analysis of the contributions of herpes simplex

-57-

virus type 1 membrane proteins to the induction of cell-cell fusion. *J. Virol.* 68:7586-7590.

20. De Schryver, A., and A. Meheus. 1990. Epidemiology of sexually transmitted diseases: the global picture.

5 Bull. World Health Organ. 68:639-654.

21. DeLuca, N. A., A. M. McCarthy, and P. A. Schaffer. 1985. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate early regulatory protein ICP4. *J.*

10 *Virol.* 56:558-570.

22. Devlin, H., P. Geary, D. Pavan-Langston, Z. Dori, and E. C. Dunkel. 1993. Efficacy of CTC topical therapy during HSV-1-induced epithelial and stromal keratitis in the rabbit. *Invest. Ophthal. Vis. Sci.* 34:1348.

15 23. Di Simone, C., and J. D. Baldeschwieier. 1992. Membrane fusion of mumps virus with ghost erythrocytes and CV-1 cells. *Virology.* 191:338-345.

24. Dixon, R. F., and P. A. Schaffer. 1980. Fine structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. *J. Virol.* 36:189-203.

25 25. Dunkel, E. C., P. A. Geary, J. Brooks, and D. Pavan-Langston. 1991. CTC 23 efficacy in vitro and on HSV-1-induced ocular epithelial and stromal disease in the rabbit. *Antivir. Res. Supp.* 1:135.

30 26. Dyer, A. P., B. W. Banfield, D. Martindale, D.-M. Spannier, and F. Tufaro. 1997. Dextran sulfate can act as an artificial receptor to mediate a type-specific herpes simplex virus infection via glycoprotein B. *J. Virol.* 71:191-198.

35 27. Elion, G. B., P. A. Furman, J. A. Fyfe, P. de Mirnada, L. Beauchamp, and H. J. Schaeffer. 1977. Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl) guanine. *Proc. Natl. Acad. Sci. USA.* 74:5716-5720.

-58-

28. Ellis, M. N., P. M. Keller, J. A. Fyfe, J. L. Martin, J. F. Rooney, S. E. Straus, S. N. Lehrman, and D. W. Barry. 1987. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. *Antimicrob. Agents Chemother.* 31:1117-1125.

5 29. Erice, A., C. Gil-Roda, J.-L. Perez, H. H. Balfour Jr., K. J. Sannerud, M. N. Hanson, G. Boivin, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. *J. Infect. Dis.* 175:1087-1092.

10 30. Erlich, K. S., L. Mills, P. Chatis, G. J. Mertz, D. F. Busch, S. E. Follansbee, R. M. Grant, and C. S. Crumpacker. 1989. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. *N. Engl. J. Med.* 320:293-296.

15 31. Frenkel, N., S. Silverstein, E. Cassai, and B. Roizman. 1973. RNA synthesis in cells productivity infected with herpes simplex virus. VIII. Control of transcription and of transcript abundancies of unique and common sequences of herpes simplex 1 and 2. *J. Virol.* 11:886-892.

20 32. Fyfe, J. A., P. M. Keller, P. A. Furman, R. L. Miller, and G. B. Elion. 1978. Thymidine kinase from herpes simplex virus phosphorylates the antiviral compound, 9-(2-hydroxyethoxymethyl) guanine. *J. Biol. Chem.* 253:8721-8727.

25 33. Gaudin, Y., C. Tuffereau, P. Durrer, J. Brunner, A. Flamand, and R. Ruigrok. 1999. Rabies virus-induced membrane fusion. *Molec. Membr. Biol.* 16:21-31.

30 34. Gerster, T., and R. G. Roeder. 1988. A herpesvirus trans-activating protein interacts with transcription factor OTF-1 and other cellular proteins. *Proc. Natl. Acad. Sci. USA.* 85:6347-6351.

35

-59-

35. Hall, L. M., K. G. Draper, R. J. Frink, R. H. Costa, and E. K. Wagner. 1982. Herpes simplex virus mRNA species mapping in EcoRI F fragment. *J. Virol.* 43:594-609.
- 5 36. Herold, B. C., R. J. Visalli, N. Susmarsi, C. R. Brandt, and P. G. Spear. 1994. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. *J. Gen. Virol.* 75:1211-1222.
- 10 37. Herold, B. C., D. WuDunn, N. Soltys, and P. G. Spear. 1991. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. *J. Virol.* 65:1090-1098.
- 15 38. Hoekstra, D., T. de Boer, K. Klappe, and J. Wilschut. 1984. Fluorescence method for measuring the kinetics of fusion between biological membranes. *Biochemistry*. 23:5675-5681.
39. Hoekstra, D., K. Klappe, T. de Boer, and J. Wilschut. 1985. Characterization of the fusogenic properties of 20 Sendai virus: kinetics of fusion with erythrocyte membranes. *Biochemistry*. 24:4739-4745.
40. Holland, L. E., R. M. Sandri-Goldin, A. L. Goldin, J. C. Glorioso, and M. Levine. 1984. Transcriptional and genetic analyses of the herpes simplex virus type 1 genome: coordinates 0.29 to 0.45. *J. Virol.* 49:947-959.
- 25 41. Honess, R. W., and B. Roizman. 1974. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. *J. Virol.* 14:8-19.
- 30 42. Honess, R. W., and B. Roizman. 1975. Regulation of herpesvirus macromolecular synthesis: Sequential transition of polypeptide synthesis requires functional viral polypeptides. *Proc. Natl. Acad. Sci. USA*. 72:1276-1280.
- 35 43. Hughson, F. M. 1997. Enveloped viruses: A common mode of membrane fusion? *Curr. Biol.* 7:R565-569.

-60-

44. Hwang, C. B. C., K. L. Ruffner, and D. M. Coen. 1992. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. *J. Virol.* 66:1774-1776.
- 5 45. Hyndiuk, R. A., and D. B. Glasser. 1986. Herpes simplex keratitis., p. 343-368. In K. Tabbarra, and Hyndiuk, R.A. (ed.), *Infections of the eye. Diagnosis and management*. Little Brown, Boston.
- 10 46. Jones, K. A., and R. Tjian. 1985. SPL binds to promoter sequences and activates herpes simplex virus immediate-early gene transcription in vitro. *Nature*. 317:179-182.
47. Keay, S., and B. Baldwin. 1991. Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment. *J. Virol.* 15 65:5124-5128.
48. La Boissiere, S., T. Hughes, and P. O'Hare. 1999. HCF-dependent nuclear import of VP16. *EMBO J.* 18:480-489.
49. Lamb, R. A., S. B. Joshi, and R. E. Dutch. 1999. The paramyxovirus fusion protein forms an extremely stable core trimer: structural parallels to influenza virus haemagglutinin and HIV-1 gp41. *Molec. Membr. Biol.* 20 16:11-19.
50. Laquerre, S., R. Argnani, D. B. Anderson, S. Zucchini, R. Manservigi, and J. C. Glorioso. 1998. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. *J. Virol.* 72:6119-6130.
51. Laughlin, C. A., R. J. Black, J. Feinberg, D. J. Freeman, J. Ramsey, M. A. Ussery, and R. J. Whitley. 30 1991. Resistance to antiviral drugs: although relatively new and poorly understood, viral resistance to drugs is an increasingly significant clinical issue. *ASM News*. 57:514-517.
- 35 52. Liesegang, T. J. 1989. Epidemiology of ocular herpes simplex. Natural history in Rochester, Minn, 1950

-61-

through 1982. Arch. Ophthalmol. 107:1160-1165.

53. Liesegang, T. J., L. J. Melton, P. J. Daly, and D. M. Ilstrup. 1989. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch. Ophthalmol. 107:1155-1159.

54. Liium, E. K., C. A. Panagiotidis, X. Wen, and S. J. Silverstein. 1996. Repression of the a0 gene by ICP4 during a productive herpes simplex virus infection. J. Virol. 70:3488-3496.

10 55. Liium, E. K., and S. J. Silverstein. 1997. Mutational analysis of the herpes simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential a27 gene. J. Virol. 71:8602-8614.

15 56. Louie, A. Y., and T. J. Meade. 1998. A cobalt complex that selectively disrupts the structure and function of zinc fingers. Proc. Natl. Acad. Sci. USA. 95:6663-6668.

57. Loyter, A., V. Citovsky, and R. Blumenthal. 1988. The use of fluorescence dequenching measurement to follow 20 viral membrane fusion. Methods Biochem. Anal. 33:129-164.

58. Mackem, S., and B. Roizman. 1982. Differentiation between a promoter and regulator regions of herpes simplex virus 1: The functional domains and sequence of 25 a movable a regulator. Proc. Natl. Acad. Sci. USA. 79:4917-4921.

59. Mackem, S., and B. Roizman. 1982. Regulation of a genes of herpes simplex virus: The a27 promoter-thymidine kinase chimera is positively regulated in converted L 30 cells. J. Virol. 43:1015-1023.

60. Mackem, S., and B. Roizman. 1982. Structural features of the herpes simplex virus alpha-gene 4, 0 and 27 promoter-regulatory sequences which confer alpha-regulation on chimeric thymidine kinase genes. J. 35 Virol. 44:939-946.

61. McMahan, L., and P. A. Schaffer. 1990. Repressing and

-62-

enhancing functions of the herpes simplex virus regulatory protein ICP27 map to C-terminal regions and are required to modulate viral gene expression very early in infection. *J. Virol.* 64:3471-3485.

5 62. Miller, N., and L. M. Hutt-Fletcher. 1988. A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus. *J. Virol.* 62:2366-2372.

10 63. Montgomery, R. I., M. S. Warner, B. J. Lum, and P. G. Spear. 1996. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. *Cell.* 87:427-436.

15 64. Navarro, D., P. Paz, and L. Pereira. 1992. Domains of herpes simplex virus 1 glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion. *Virology.* 186:99-112.

20 65. Novotny, M. J., M. L. Parish, and P. G. Spear. 1996. Variability of herpes simplex virus gL and anti-gL antibodies that inhibit cell fusion but not viral infectivity. *Virology.* 221:1-13.

25 66. Nugier, F., J. N. Colin, M. Aymard, and M. Langlois. 1992. Occurrence and characterization of acyclovir-resistance herpes simplex virus isolates: report on a two-year sensitivity screening survey. *J. Med. Virol.* 36:1-12.

30 67. O'Hare, P., C. R. Goding, and A. Haigh. 1988. Direct combinatorial interaction between a herpes simplex virus regulatory protein and a cellular octamer-binding factor mediates specific induction of virus immediate-early gene expression. *EMBO J.* 7:4231-4238.

35 68. Ostrow, R. S., S. Coughlin, R. C. McGlennen, Z. Liu, D. Zelterman, and A. J. Faras. 1994. Topical CTC-96 accelerates wart growth in rabbits infected with cottontail rabbit papillomavirus. *Antivir. Res.* 24:27-35.

 69. Pinol-Roma, S., S. A. Adam, Y. Do Choi, and G.

-63-

Dreyfuss. 1989. Ultraviolet-induced cross-linking of RNA to proteins in vivo. *Methods Enzym.* 180:410-418.

70. Pope, L. E., J. F. Marcelletti, L. R. Katz, J. Y. Lin, D. H. Katz, M. L. Parish, and P. G. Spear. 1998. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. *Antivir. Res.* 40:85-94.

10. Post, L. E., S. Mackem, and B. Roizman. 1981. Regulation of alpha genes of HSV: expression of chimeric genes produced by fusion of thymidine kinase with alpha gene promoters. *Cell.* 24:555-565.

15. Preston, C. M. 1979. Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. *J. Virol.* 29:275-284.

73. Rajcani, J., and A. Vojvodova. 1998. The role of herpes simplex virus glycoproteins in the virus replication cycle. *Acta Virol.* 42:103-118.

74. Reusser, P. 1998. Current concepts and challenges in the prevention and treatment of viral infections in immunocompromised cancer patients. *Support Care Cancer.* 6:39-45.

75. Rice, S. A., and D. M. Knipe. 1988. Gene-specific trans-activation by the herpes simplex virus type 1 alpha protein ICP27. *J. Virol.* 62:3814-3823.

20. 76. Roizman, B. 1968. An inquiry into the mechanisms of recurrent herpes infections in man., p. 283. In M. Pollard (ed.), *Perspectives in virology.*, vol. 4. Harper & Row, New York.

30. 77. Schnipper, L. E., and C. S. Crumpacker. 1980. Resistance of herpes simplex virus to acycloguanosine: role of thymidine kinase and DNA polymerase loci. *Proc. Natl. Acad. Sci. USA.* 77:2270-2273.

78. 35. Shieh, M.-T., D. WuDunn, R. I. Montgomery, J. D. Esko, and P. G. Spear. 1992. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans.

-64-

J. Cell Biol. 116:1273-1281.

79. Showalter, S. D., M. Zweig, and B. Hampar. 1981. Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP4. Infec. Immun. 34:684-692.

5 80. Sinangil, F., A. Loyter, and D. J. Volsky. 1988. Quantitative measurement of human immunodeficiency virus and cultured cells using membrane fluorescence dequenching. FEBS Lett. 239:88-92.

10 81. Sodeik, B., M. W. Ebersold, and A. Helenius. 1997. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J. Cell Biol. 136:1007--1021.

15 82. Spear, P. G. 1993. Entry of alphaherpesviruses into cells. Sem. Virol. 4:167-180.

83. Spear, P. G. 1985. Glycoproteins specified by herpes simplex virus., p. 315-356. In B. Roizman (ed.), The Herpesviruses., vol. 3. Plenum Press, New York.

20 84. Stewart, J. A., S. E. Reff, P. E. Pellet, L. Corey, and R. J. Whitely. 1995. Herpesvirus infection in persons infected with human immunodeficiency virus. Clin. Infec. Dis. 21 Supp. 1:S114-120.

85. Swanstrom, R. I., K. Pivo, and E. K. Wagner. 1974. Restricted transcription of the herpes simplex virus genome occurring early after infection and in the presence of metabolic inhibitors. Virology. 66:140-150.

25 86. Terry-Allison, T., R. Montgomery, J. C. Whitbeck, R. Xu, G. H. Cohen, R. J. Eisenberg, and P. G. Spear. 1998. HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion. J. Virol. 72:5802-5810.

30 87. Thomas, J., and B. T. Rouse. 1997. Immunopathogenesis of herpetic ocular disease. Immunol. Res. 16:375-386.

88. Vogt, P. E., C. B. Hartline, T. P. Gerchow, and E. R. Kern. 1992. Antiviral activity of a series of cobalt containing complexes against herpesvirus infection in

-65-

vitro and in vivo. *Antivir. Res.* 17S:114.

89. Watson, R. J., and J. B. Clements. 1978. Characterization of transcription-deficient temperature-sensitive mutants of herpes simplex virus. *Virology.* 91:364-379.

5 90. Weissenhorn, W., A. Dessen, L. J. Calder, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1999. Structural basis for membrane fusion by enveloped viruses. *Molec. Membr. Biol.* 16:3-9.

10 91. Whitley, R. J. 1990. Herpes simplex viruses., p. 1843-1887. In B. N. Fields, and Knipe, D.M. (ed.), *Virology*, 2 ed. Raven Press, Ltd., New York.

92. Wood, M. J. 1996. Antivirals in the context of HIV disease. *J. Antimicrob. Chemother.* 37 Supp. B:97-112.

15 93. Wooley, P. H., and J. D. Whalen. 1992. The influence of superoxide scavenging compound CTC 23 on type II collagen-induce arthritis in mice. *Agents Actions.* 35:273-279.

20 94. WuDunn, D., and P. G. Spear. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. *J. Virol.* 63:52-58.

95. Zhou, Z. H., D. H. Chen, J. Jakana, F. J. Rixon, and W. Chiu. 1999. Visualization of tegument-capsid interactions and DNA in intact herpes simplex virus type 1 virions. *J. Virol.* 73:3210-3218.

25 96. Zhu, Q., and R. J. Courtney. 1988. Chemical crosslinking of glycoproteins on the envelope of herpes simplex virus. *Virology.* 167:377-384.


30

35

-66-

What is claimed is:

1. A method of preventing the infection of a cell by a virus comprising contacting the cell with a compound having the structure:



wherein each of R^1 , R^2 , R^3 , and R^4 is the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;

wherein R^5 is hydrogen, a halide, an alkoxide group, an alkyl group or OH;

wherein each of L and L' is the same or different and is NH_3 , 2-methylimidazole, an imidazole, or a substituted derivative of an imidazole; and


wherein Q^- is a soluble, pharmaceutically acceptable negative ion,

so as to thereby prevent infection of the cell by the virus.

2. The method of claim 1, wherein each of R^1 , R^2 , R^3 , and R^4 is CH_3 ; R^5 is H or Cl; $L=L'$ = imidazole or 2-methylimidazole; and Q^- is Cl^- or Br^- .

-67-

3. The method of claim 1, wherein the compound has the structure:



wherein L=L'= 2-methylimidazole.

4. The method of claim 1, wherein the virus is an enveloped virus

5. The method of claim 1, wherein the virus is a non-enveloped virus.

6. The method of claim 4, wherein the enveloped virus is selected from the group consisting of a herpes virus, varicella-zoster virus, vesicular stomatitis virus, and influenza virus.

7. The method of claim 6, wherein the enveloped virus is a herpes virus.


8. The method of claim 6, wherein the enveloped virus is an influenza virus.

9. The method of claim 5, wherein the non-enveloped virus is selected from the group consisting of poliovirus and adenovirus.

-68-

10. The method of claim 9, wherein the non-enveloped virus is adenovirus.

11. An antiviral composition comprising an antiviral effective amount of a compound having the structure:



wherein each of R^1 , R^2 , R^3 , and R^4 is the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;

wherein R^5 is hydrogen, a halide, an alkoxide group, an alkyl group or OH;

wherein each of L and L' is the same or different and is NH_3 , 2-methylimidazole, an imidazole, or a substituted derivative of an imidazole; and

wherein Q^- is a soluble, pharmaceutically acceptable negative ion, and a carrier.

12. A method of treating a cell infected by a virus comprising contacting the cell with the antiviral composition of claim 11, so as to thereby treat the cell.

-69-


13. A method of treating a subject infected with a virus comprising administering to the subject the antiviral composition of claim 11, so as to thereby treat the subject.
14. A method of preventing infection of a subject by a virus comprising administering to the subject the antiviral composition of claim 11, so as to thereby prevent infection of the subject by the virus.
15. The method of claim 12, wherein the form of administration is selected from the groups consisting of oral, intramuscular injection, intraperitoneal injection, aerosol, and intravenous infusion.
16. A method of sterilizing surgical and medical tools and equipment comprising contacting the tools and equipment with the antiviral composition of claim 11.
17. A method of sterilizing a room comprising spraying in the room a fine mist comprising the antiviral composition of claim 11.
18. A method of sterilizing air comprising dispersing in the air a fine mist comprising the antiviral composition of claim 11.
19. The antiviral composition of claim 11 formulated with a pharmaceutically acceptable carrier so as to result in an antiviral pharmaceutical composition.
20. The antiviral composition of claim 18 prepared in a form selected from the group consisting of a tablet, a caplet, a pill, an aerosol, an inhalant, a solution, a powder, a capsule, an ointment, an aqueous suspension,

-70-

an oily suspension, a syrup, and an elixir.

1/19

Figure 1



2/19

Figure 2A






Figure 2B



3/19

Figure 3



4/19






Figure 4

5/19**Figure 5**

6/19**Figure 6**

7/19





Figure 7

8/19

- CTC-96**+ CTC-96****Figure 8**

9/19







Figure 9

10/19


-CTC-96**+CTC-96****Figure 10A**

11/19
-CTC-96

10x




25x



+CTC-96

10x




25x



0hpi

10hpi

10x



40x





Figure 10B

12/19

Figure 11

-CTC-96


13/19

Figure 12


Sample	Drug	Relative Counts	
		1X	0.1X
1	-	6	ND
1	-	5	ND
1	+	8	ND
1	+	5	ND
M9	-	1	1
9	-	237	40
9	-	289	38
9	+	16	2
9	+	17	2


14/19

Figure 13



15/19

Figure 14

16/19**Figure 15**


17/19

Figure 16

<u>Treatment</u>	<u>Nuc</u>	<u>Cyto</u>
None/ 5 min	-	
None/ 1 hr	■	
CTC-96/ 1hr	-	
Cyclo/ 1 hr	■	


18/19

Figure 17



19/19

Figure 18



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/18488

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/295, 31/70, 38/02

US CL : 514/6, 44, 501; 424/dig 6, 1.65, 1.69, 1.73

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/6, 44, 501; 424/dig 6, 1.65, 1.69, 1.73

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 6,008,190 A (MEADE et al.) 28 December 1999 (28.12.99), see column 1, lines 20-21, column 17, lines 20-34.	1-20
X	US 5,049,557 A (DORI et al.) 17 September 1991 (17.09.91) see abstract.	11, 19, 20
A		1-10, 12-18
X	US 5,756,491 A (DORI) 26 May 1998 (26.05.98) see abstract, column 3, lines 8-17, column 6, lines 8-45, column 16, line 42 to column 20, line 17.	1-20

<input checked="" type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
"	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
06 SEPTEMBER 2000	22 SEP 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer DONNA JAGOE Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/18488

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----	Database Medline on STN, US National Library of Medicine (Bethesda, MD, USA) No. 98427882. ASBELL et al. 'Efficacy of Cobalt Chelates in the Rabbit Eye Model for Epithelial Herpetic Keratitis'. Cornea September 1998, Vol. 17, No. 5, 550-557, see abstract.	1-4, 6-8, 11-14, 19-20 -----
A ----	Database BIOSIS on STN, No. 1997-20714. BOURNE et al. 'Evaluation of the Antiviral Activity of an Organometallic Compound in the Guinea Pig Model of Genital Herpes'. Antiviral Research. 1997, Vol. 34, No. 2, A81.	5, 9-10, 15-18 -----
		1-4, 6-8, 11-14, 19-20 ----- 5, 9-10, 15-18

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/18488

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST 2.0, STN, files ADISALERTS, ADISINSIGHT, AIDSLINE, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DDFB, DDFU, DGENE, DRUGB, DDFU, DOENE, DRUGB, DRUGLAUNCH, DRUGNONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDLINE., NAPRALERT, NLDB, PHIC, PHIN, SCISEARCH, TOXLINE, TOXLIT, USPATFULL. SEARCH TERMS: RN # 158318-97-9, CTC 96, ANTI-VIRAL,

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)